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ABSTRACT
Sarcomas are broadly defined as cancers that form in the bone, soft tissue, or con-
nective tissue. While they represent only 1% of all cancers in the United States,
sarcomas constitute 12% of all childhood cancers. Five-year survival has not changed
in over 40 years. The only clinically accepted indicator of pathologic response and
disease-free survival is percent tumor-cell necrosis at time of surgery—there are no
established prognostic markers before surgery. Unfortunately, 40–70% of patients
have a poor pathologic response and attempts to modify treatment to improve their
outcomes have been unsuccessful. Diffuse Optical Spectroscopic Imaging (DOSI)
is a non-invasive, functional imagining technique that has been previously imple-
mented to predict pathologic response in patients with breast cancer. Specifically,
DOSI combines frequency amplitude modulated near-infrared light and broadband
continuous wave light to measure quantitative concentrations of oxyhemoglobin, de-
oxyhemoglobin, water, and lipids. This project developed and validated DOSI as a
new non-invasive measurement modality to track treatment for sarcomas. For the
first time, the optical properties and functional hemodynamic information of the dis-
tal femur, tibia, and humerus were characterized in normal volunteers. DOSI demon-
vii
strated the ability to measure optical properties and functional information at several
sarcoma locations throughout the course of treatment. It was able to differentiate
between healthy and sarcoma tissues within a patient. Improvements made to the
instrumentation will facilitate future measurements in this patient population. In the
future, DOSI may provide a way to monitor treatment response and improve patient
outcomes.
viii
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1Chapter 1
Background and significance
1.1 Sarcomas
1.1.1 Epidemiology and diagnosis
Sarcomas are malignant tumors of the connective tissue, such as bone, muscle, and
cartilage (Klein and Siegal, 2006). While they represent less than 1% of cancers in
the United States (National Cancer Institute, b; National Cancer Institute, a), they
comprise 12% of all childhood cancers (Howlander et al., 2016). Osteosarcoma and
Ewing sarcoma are the two most common bone malignancies in children and young
adults (National Cancer Institute, b; Mirabello et al., 2009), representing 5% of all
pediatric cancers (Howlander et al., 2016). Soft tissue sarcomas are another common
malignancy and represent 6% of all pediatric cancers (Howlander et al., 2016).
Peak incidence of bone cancer is in the second decade of life (National Cancer
Institute, b; Mirabello et al., 2009), occurring in males slightly more often than in
females (National Cancer Institute, b; National Cancer Institute, a; Mirabello et al.,
2009). Bone cancers, especially osteosarcomas, occur most frequently in the long
bones of the body (Klein and Siegal, 2006; Mirabello et al., 2009; Bielack et al.,
2002). Sarcoma symptoms include pain and swelling at the bone and joint, often
accompanied by a soft tissue mass (Bielack et al., 2002; Davis et al., 1994; Biermann
et al., 2013; Bernstein et al., 2006). After imaging studies, such as MRI, the diagnosis
is confirmed by a biopsy (Hosalkar and Dormans, 2004).
21.1.2 Treatment and survival
Before 1970, amputation was the primary treatment for sarcomas (Hosalkar and Dor-
mans, 2004; Link et al., 1986). Despite local control, the overall survival at 5 years
was less than 20% (Link et al., 1986; Uribe-Botero et al., 1977; Dahlin and Coven-
try, 1967). Thus all patients are assumed to have subclinical metastasis (Klein and
Siegal, 2006; Hosalkar and Dormans, 2004; Link et al., 1986). With the introduction
of chemotherapy in the early 1970’s, 5 year disease-free survival and overall survival
increased from less than 20% to almost 70% (National Cancer Institute, b; National
Cancer Institute, a; Mirabello et al., 2009; Link et al., 1986; Uribe-Botero et al., 1977;
Dahlin and Coventry, 1967).
Sarcomas are now treated as a systemic disease using multiagent neoadjuvant
(presurgical) chemotherapy followed by surgery and postoperative chemotherapy (Hos-
alkar and Dormans, 2004; Meyers et al., 1992; Mehren et al., 2014). Chemotherapy
drugs such as Adriamycin (doxorubicin), cisplatin, methotrexate, and ifosfamide are
delivered cyclically for a few months before surgical resection or amputation (Carrle
and Bielack, 2006; The ESMO/European Sarcoma Network Working Group, 2014;
Wittig et al., 2002). Despite these advances in treatment, disease-free survival and
overall survival for localized disease have stagnated for the last 40 years, remaining at
approximately 70% survival(National Cancer Institute, b; National Cancer Institute,
a; Mirabello et al., 2009; Link et al., 1986; Uribe-Botero et al., 1977; Dahlin and
Coventry, 1967).
Even though neoadjuvant chemotherapy and adjuvant chemotherapy have similar
disease-free survival rates (Meyers et al., 1992), neoadjuvant chemotherapy is the
standard of care (Marina et al., 2004). Neoadjuvant chemotherapy is favored because
it gives early systemic treatment for subclinical microscopic metastases (Rosen et al.,
1979), improves the quality of the surgical margin (Hosalkar and Dormans, 2004),
3increases limb-saving surgeries (Bielack et al., 2002; Hosalkar and Dormans, 2004;
Marina et al., 2004; Bacci et al., 2005), and assesses chemotherapy response at time
of surgery (Marina et al., 2004).
1.1.3 Prognostic markers
The only clinically accepted prognostic marker is histologic response to neoadjuvant
chemotherapy (Bieling et al., 1996). Good histologic response is typically defined as
having greater than 90% tumor-cell necrosis at time of surgery and is correlated with
longer disease-free survival, event-free survival, and overall survival rates (Meyers
et al., 1992; Hosalkar and Dormans, 2004; Provisor et al., 1997; Wunder et al., 1998)
Unfortunately, this biomarker can only be determined at the time of surgery, weeks or
months after intensive chemotherapy (Bacci et al., 2003; Bielack et al., 2002; Hauben
et al., 2002).
At the time of surgery, approximately 40–70% of patients have a poor histologic
response (Hauben et al., 2002; Asha et al., 2012). For patients with a poor response,
salvage therapy modifies the post-surgery chemotherapy regimen in hopes of better
patient outcomes. Since an initial success in the 1980’s (Rosen et al., 1979), salvage
therapy has been unsuccessful at improving the outcome of poor responders (Meyers
et al., 1992; Carrle and Bielack, 2006; Provisor et al., 1997; Winkler et al., 1988; The
ESMO/European Sarcoma Network Working Group, 2014). The delayed evaluation
of treatment response could be a reason for continued poor outcomes (Asha et al.,
2012), emphasizing the need to identify poor responders early in treatment before
surgery.
Other prognostic markers, such as tumor location (Mirabello et al., 2009; Bielack
et al., 2002; Meyers et al., 1992), initial tumor size (Bielack et al., 2002; Bieling
et al., 1996), intratumoral microvessel density (Kreuter et al., 2004), disease stage
(Mirabello et al., 2009), and metastasis (Bielack et al., 2002), have been proposed, but
4they remain unverified and cannot be used as a clinical recommendation. Similarly,
the molecular marker alkaline phosphatase has been suggested (Meyers et al., 1992;
Bacci et al., 2005; Levine and Rosenberg, 1979; Bacci et al., 2006), but it also lacks
validation and loses it prognostic significance in multivariate analyses (Bielack et al.,
2002; Marina et al., 2004).
Imaging techniques have been mostly unsuccessful in predicting chemotherapy
response in sarcoma (The ESMO/European Sarcoma Network Working Group, 2014;
Bajpai et al., 2011; Sanchez et al., 1990). Due to the bony nature of many sarcomas,
volumetric changes may not occur despite responding to treatment (Bajpai et al.,
2011), rendering many structural imaging techniques unhelpful. For changes to be
seen on X-rays, 30–40% of the bone must be destroyed (Hosalkar and Dormans, 2004).
Diffuse weighted (DW) MRI has had mixed results detecting tumor viability and it
remains unverified (Bajpai et al., 2011; Sanchez et al., 1990; Moffat et al., 2006;
Markus Uhl et al., 2006). Recently, the functional imaging techniques FDG PET/CT
found that tumor necrosis at time of diagnosis was correlated with pathologic response
and mortality (Rakheja et al., 2013). However, these techniques cannot be used for
frequent treatment monitoring because of cost, access, and potential harm to the
patient from radiation or exogenous contrast agents (Facey et al., 2007; Meertens
et al., 2018). Thus, tumor response to chemotherapy remains the best prognostic
marker (Bielack et al., 2002; Davis et al., 1994; Meyers et al., 1992; Bacci et al.,
2005) for sarcoma and finding a new marker earlier in treatment is a priority.
1.2 Diffuse Optical Spectroscopic Imaging
1.2.1 Instrumentation
Diffuse Optical Spectroscopic Imaging (DOSI) is a noninvasive, nondestructive, non-
ionizing, functional imaging technique that holds potential as a new prognostic tool for
5sarcoma. DOSI measures quantitative concentrations of functional hemodynamic in-
formation (chromophores), such as oxyhemoglobin (HbO2), deoxyhemoglobin (HHb),
water, and lipids. The DOSI system described here was originally designed for breast
cancer and has been extensively described (Tromberg et al., 2016; No et al., 2008).
The system is compact and fits on a medical cart, allowing bedside access dur-
ing chemotherapy. The system acquires both frequency-domain and continuous wave
(broadband) measurements. It has a handheld probe that delivers amplitude mod-
ulated near-infrared (NIR) light and broadband light to the tissue via 400 µm and
1-mm optical fibers, respectively. Light levels delivered to the tissue are within ANSI
limits for skin exposure.
For the frequency-domain measurements, light from four lasers (659, 689, 781,
and 829 nm) is amplitude modulated in a sweep from 50 to 500 MHz and detected
by an avalanche photodiode (APD) with a 1-mm active area (C5658 with detector S-
6045, Hamamatsu Photonics, Hamamatsu, Japan). Broadband light from a tungsten-
halogen lamp is detected by an NIR spectrometer (650 to 1000 nm). The APD and
the fiber bundle leading to the spectrometer are embedded in the handheld probe.
1.2.2 Optical properties and functional hemodynamic information calcu-
lations
DOSI measures broadband absorption by combing frequency-domain and continu-
ous wave measurements. The optical properties, absorption and reduced scattering
coefficients (µa and µ
′
s, respectively), are calculated from simultaneously fitting cal-
ibrated frequency-domain amplitude and phase measurements from 50 to 400 MHz
to a P1 diffusion approximation of the radiative transport equation, typically assum-
ing a homogenous, semi-infinite material, although multilayer models have previously
been developed (Haskell et al., 1994; Pham et al., 2000). Broadband absorption is
fit and scaled to the frequency-domain absorption measurements (Pham et al., 2000;
6Bevilacqua et al., 2000; The MathWorks Inc., 2014). Using the broadband absorption
and known extinction coefficients (Pope and Fry, 1997; Kou et al., 1993; van Veen
et al., 2004; Zijlstra et al., 2000) quantitative concentrations of oxyhemoglobin, de-
oxyhemoglobin, water, and lipids are calculated using Beer’s Law. In addition, total
hemoglobin concentration (THC) and tissue oxygen saturation (StO2) are calculated
from oxyhemoglobin and deoxyhemoglobin concentrations.
1.2.3 Potential as a prognostic tool
DOSI has been studied extensively in the context of breast cancer, where it has
been shown that functional hemodynamic information measured using DOSI is corre-
lated with pathologic response as early as the first day after the start of neoadjuvant
chemotherapy (Ueda et al., 2012; Roblyer et al., 2011; Cerussi et al., 2011). Similar
optical biomarkers may exist in sarcoma. Since DOSI does not rely on structural
changes, but is sensitive to tumor metabolism and necrosis, it may provide earlier
assessments of treatment response than other available methods.
1.2.4 Previous diffuse optics work in bone
Many sarcomas develop in the bone and imaging will need to take place in the con-
text of lipid, muscle, and bone. While previous work has established diffuse optical
techniques in breast and muscle, less work has been done in bone (Sandell and Zhu,
2011; Jacques, 2013).
A recent review of optical systems used for measuring human hemodynamic mark-
ers in vivo bone tissue identified 19 studies that used NIR spectroscopy (Meertens
et al., 2018). Nine studies used continuous wave measurements to detect changes in
oxyhemoglobin and deoxyhemoglobin while three studies used multiple lasers to mea-
sure hemodynamics. Only one study used frequency-domain NIR spectroscopy. Five
studies used time-resolved NIR spectroscopy. In addition to hemodynamic markers,
7the time-resolved NIR spectroscopy studies could measure µa and µ
′
s. (One study did
not describe its NIR spectroscopy system.)
In addition, several groups have measured the optical properties of human bone
in vivo using near infrared spectroscopy. The absorption and reduced scattering coef-
ficients of the patella and bones in the index finger were respectively measured using
frequency-domain diffuse optical spectroscopy and tomography (Farzam et al., 2013;
Xu et al., 2001). With a time resolved transmittance system, the optical properties
for the manubrium, forearm, forehead, and calcaneous were measured in transmission
(Pifferi et al., 2004; Sekar et al., 2015b; Sekar et al., 2015a). The optical properties for
the forehead, tibia, radius, ulna, and greater trochanter of the femur have also been
measured with time resolved reflectance spectroscopy (Matcher et al., 1997; Sekar
et al., 2015a; Doornbos et al., 1999).
Other near infrared diffuse optical systems have been used to measure the optical
properties of ex vivo animals bones such as bovine dry bone matrix (Pifferi et al.,
2004), chicken bone (Xu et al., 2001), pig skull (Firbank et al., 1993), horse bone
(Ugryumova et al., 2004), and rabbit cartilage (Beek et al., 1997).
1.3 Goal of this dissertation
As a NIR system, DOSI is a noninvasive, nondestructive, nonionizing, inexpensive
tool for longitudinal hemodynamic measurements. Due to the high density and min-
eral content of bone, measuring functional hemodynamic information is a challenge
(Meertens et al., 2018). This work determines the feasibility of using DOSI in sarco-
mas.
8Chapter 2
Characterize the optical properties and
hemodynamics of normal volunteers in
common sarcoma locations
2.1 Introduction
The DOSI instrumentation was designed for pliable and optically transparent breast
tissue. This section establishes the feasibility of using DOSI to measure the angular,
rigid, and highly attenuating tissues at bony locations that are common to sarcomas.
For the first time, the optical properties and functional hemodynamic information
from adult and pediatric normal volunteers were characterized using diffuse optics
at the at the medial distal humerus, distal femur, and proximal tibia. The average
values for the three anatomic sites were quantified, differences between left and right
were quantified, and correlations between DOSI parameters and skin calipers were
computed. These values help set the stage for studies exploring bone pathologies
including sarcoma.
2.2 Methods
2.2.1 Subject eligibility and enrollment
Any volunteer was eligible as a subject for the normal volunteer study. A power
analysis based on previous exploratory DOSI studies in breast cancer and prelimi-
nary data calculated an initial target sample size of 25 subjects. The power analysis
9aimed to detect a 27% difference in mean tissue optical index (defined as deoxyhe-
moglobin*water/lipids) between neoadjuvant chemotherapy responders and nonre-
sponders with 80% power and a significance level of α=0.05, assuming equal sam-
ple sizes in responders and nonresponders with an expected 25% standard deviation
within groups. Since these are the first DOSI measurements at these anatomic loca-
tions and the power analysis was based on breast cancer, a post-hoc analysis at the
end of the study was conducted to determine if the sample size should increase based
on the physiological variability.
Normal volunteer subjects were recruited in an effort to match expected sarcoma
patient population demographics. Almost 60% of the sarcoma population is male
(National Cancer Institute, a; National Cancer Institute, b), so the target accrual
for males and females was 15 and 10, respectively. Informed consent was obtained
from all subjects. Minors (<18 years) gave assent to the best of their ability to
understand, and their parent or guardian gave written informed consent. This project
was approved by the Institutional Review Board at Boston University.
2.2.2 DOSI instrumentation
The DOSI system used to measure volunteers is a benchtop system the Biomedical
Optical Technologies Lab (BOTLab) considers to be a “gold standard” for its mea-
surements. Unlike the clinical system which is portable (Section 1.2.1), this system
spans an optical table.
Like the clinical system, the benchtop system acquires both frequency-domain and
continuous wave measurements. Unlike the clinical system, the frequency-domain
measurements use light from six lasers (658, 690, 785, 808, 830, and 850 nm) instead
of four lasers. Optical fibers deliver amplitude modulated NIR light and broadband
light to the tissue via 400 µm and 1-mm optical fibers, respectively. The light is
amplitude modulated in a sweep from 50 to 500 MHz and is detected by a 1-mm
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active area APD (C5658 with detector S-6045, Hamamatsu Photonics, Hamamatsu,
Japan). Continuous wave light from a tungsten-halogen lamp is detected by an NIR
spectrometer from 650 to 1000 nm (AvaSpec HS2040XL with a 200 µm slit, 600
lines/mm grating, and 10–12 nm FWHM spectral resolution, Avantes Inc., Broom-
field, CO, USA). Light levels delivered to the sample were within ANSI limits for
skin exposure. Figures 2·1 shows a picture of the probe sources and detectors. All
measurements for this study were taken with a source-detector separation of 28 mm.
a) b)
Figure 2·1: (a) Picture of the probe used in clinical measurements
with (b) a close-up of the broadband source and detector fibers, laser
source fiber bundle, and APD.
2.2.3 Imaging procedures
A standard DOSI measurement procedure originally developed for breast and used
for several prior published studies was modified for measurements taken in this study
(Cerussi et al., 2011; Tromberg et al., 2016). In this study, measurements were made
on the left and right medial distal humerus, distal femur, and proximal tibia.
The corners of 1 square cm grid were transferred onto the skin surface at each
location using a transparency and nonpermanent surgical marker. All subjects were
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measured 4 cm from the medial epicondyle of the humerus, on the medial epicondyle
of the femur, and 3 cm from the distal end of the patella on the right and left side
of the body. As seen in Figure 2·2, the transparency included distinctive features to
serve as a reference, e.g. freckles, moles, scars, and bone landmarks. The landmarks
helped to identify the same region of interest for any subsequent measurements.
Figure 2·2: Transparency used to transfer fiducial markers onto the
tibia of a normal volunteer.
An operator scanned the handheld probe over the square, taking a point measure-
ment at each dot. Data was processed using the methods described in Section 1.2.2 to
calculate optical properties and concentrations of oxyhemoglobin, deoxyhemoglobin,
water, and lipids.
Each subject in this study had a total of 8 measurements on the distal humerus,
8 measurements on the distal femur, and 8 measurements on the proximal tibia, a
12
total of 24 point measurements.
2.2.4 Data quality control
To be included in the dataset, the broadband reduced scattering coefficient must
follow a power law and chromophore values must be physiological (i.e. lipid and
water percentage cannot exceed 100%). Data that do not meet these requirements
were excluded. Any points over tattoos were also excluded.
2.2.5 Estimates of body fat percentage
Estimates of body fat percentage were calculated by measurements of subcutaneous
tissue. Using the Lange Skinfold Caliper (Beta Technology, Santa Cruz, California),
skinfold measurements were taken at the biceps, triceps, subscapular, and the suprail-
iac. The sum of the four skinfold measurements were converted to the equivalent fat
content as a percentage of body weight using the Lange Skinfold Caliper Operators
Manual (Beta Technology, 2008). For subjects <18, only triceps and subscapular
skinfold measurements were taken.
2.2.6 Comparison of optical properties and chromophore concentrations
The two-sided Mann-Whitney test was used to statically compare the distribution of
point measurements for left and right tissues at each bone location. For each optical
property and chromophore, the difference in means between left and right tissue was
calculated for each subject. The mean and absolute maximum changes for values
between left and right sides within an individual was calculated as the average of
differences and as the maximum absolute difference. ANOVA with Tukey’s honestly
significant difference (HSD) post hoc test compared differences between the humerus,
femur, and tibia. Pearson’s correlation coefficient quantified the relationship between
DOSI lipid concentrations at a bony location and the body fat percentage.
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An individual was measured multiple times over the course of 3 weeks to quantify
the variation within an individual. Tukeys HSD compared differences in means that
were designated significant by ANOVA. For each optical property and chromophore,
the difference between mean baseline and the mean value at each visit was calculated
for each bone; from this difference in means, the mean and absolute maximum change
was calculated as the average of differences and as the maximum absolute difference.
All statistics were calculated using SciPy 1.0.0 in Python version 2.7.13 (Python
Software Foundation, 2015; Jones et al., 2001).
2.3 Results
2.3.1 Subject enrollment
Twenty four subjects were enrolled in the study. One subject was not analyzed
due to software data processing issues—there were no issues with SNR. The subject
characteristics are shown in Table 2.1. Subjects are identified by the study number
with a three digit identifier in the form 3367-000. The protocol is approved for several
studies, so identifiers are not necessarily sequential and the first subject number is
3367-012.
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Table 2.1: Subject characteristics.
Variable Enrolled
Subjects 24
Adult (≥ 18 years) 22
Minor (<18 years) 3
Age (years)
Median 27
Range [4–46]
Sex
Male 12
Female 12
Race
White 10
Black/African-American 1
Asian 9
Multiracial 1
Unknown 3
Ethnicity
Hispanic or Latino 4
Not Hispanic or Latino 20
Adult body fat
Median (%) 21.4
Range (%) [10.5–27.8]
Off the chart (n) 1
Unknown (n) 1
2.3.2 Optical properties
Examples of µa and µ
′
s spectra for the humerus, femur, and tibia from a 25 year old
female are shown in Figure 2·3. Though the magnitude of µa differs, the spectra have
a similar shape from 650–900 nm (Figure 2·3a). At 980 nm there is a water absorption
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peak and there are notable differences in the magnitude of µa, with the tibia being
most absorbing and the femur the least. For this individual and the population, the
scattering slope and amplitude of µ′s is different for each bone (Figure 2·3b).
Figure 2·3: Example (a) µa and (b) µ′s spectra for the humerus (or-
ange), femur (blue), and tibia (green) from a 25 year old female.
Comparing bones within an individual, there were few statistical differences in
the scattering amplitude parameter. Only 4 subjects had a difference between the
humerus and tibia, and 2 subjects had a difference between the femur and tibia.
None had a statistical difference between the humerus and femur. The subjects with
statistical differences were the oldest and youngest participants. Scattering slope had
more differences between the bones. Fifteen subjects had differences between the tibia
and humerus, 11 had differences between the tibia and femur, and 6 had differences
between the femur and humerus.
Optical properties were compared for measurements taken on the left and right
tissues at each bony location for each subject. The humerus had the most subjects
with statistical differences between the sides—5 subjects had a difference in the scat-
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tering slope and 11 had a difference in the scattering amplitude. Eight subjects had
differences in the scattering amplitude and three had differences in the scattering
slope in the femur. In the tibia, 1 subject had a difference in the scattering amplitude
and slope, with an additional 3 had differences in the scattering amplitude.
2.3.3 Chromophore concentrations
The mean and standard deviation of oxyhemoglobin, deoxyhemoglobin, water, lipids,
total hemoglobin, and tissue oxygen saturation are reported for each bone in Table
2.2.
Table 2.2: Mean and standard deviation for chromophore concentra-
tions in bones.
Humerus Femur Tibia
HbO2 (µM) 35.4 (16.8) 31.6 (16.3) 27.9 (11.9)
HHb (µM) 11.7 (3.3) 10.5 (3.1) 10.9 (3.1)
Water (%) 12.8 (3.1) 15.2 (3.8) 27.7 (12.1)
Lipids (%) 37.3 (14.0) 29.4 (14.3) 25.2 (10.0)
THC (µM) 47.1 (19.1) 42.1 (18.2) 38.9 (12.9)
StO2 (%) 73.1 (6.0) 72.7 (7.9) 69.8 (9.5)
The distribution of chromphores for each bone is shown in the violin plots of
Figure 2·4. Like a histogram plot, the width of the violin is scaled by the number of
observations in that bin, but a kernel density estimation “smooths” the underlying
distribution (Waskom et al., 2017). Within each violin plot is a box plot. The
humerus, femur, and tibia are statistically different from each other in water and
lipid concentrations (Figure 2·4c–d). The humerus is different in total hemoglobin
concentration (Figure 2·4e) while the tibia is different in tissue oxygen saturation
(Figure 2·4f). The humerus and tibia statistically differ in oxyhemoglobin (Figure
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2·4a) while the humerus and femur differ in deoxyhemoglobin (Figure 2·4b).
Differences in chromophore concentrations were compared between left and right
tissues. At the population level, only water is significantly different between right
and left sides at the femur (p = 0.003). The average water concentration on the right
side was 27.05% and the left side was 28.2%. Within individuals, of the 24 subjects,
12 had some statistical difference in chormophore concentration between the left and
right humerus. The most common differences occurred in tissue oxygen saturation (n
= 9) or water (n = 9). The least common chromophore to be statistically different
was oxyhemoglobin, deoxyhemoglobin, and total hemoglobin concentrations (n = 6
for all). Twelve subjects had statistical differences in the femur. Water was the most
frequently statistically different chromophore for subjects (n = 6). Deoxyhemoglobin
(n = 3) and lipid (n = 2) were the least frequently significant. The left and right
tibia were most similar for subjects, with only 6 individuals having some statistical
difference. Oxyhemoglobin was the most frequently statistically different (n = 4),
while deoxyhemoglobin (n = 1), lipid (n = 1) and tissue oxygen saturation (n = 1)
were the least frequently different.
The mean and absolute maximum changes for chromophore values between left
and right sides within an individual are shown in Table 2.3. The humerus had the
largest maximum change in oxyhemoglobin, deoxyhemoglobin, and total hemoglobin
concentration. The tibia had the smallest maximum change in oxyhemoglobin and
total hemoglobin concentration while the femur had the smallest maximum change
in deoxyhemoglobin. Water and tissue oxygen saturation had the smallest maximum
changes in the femur. Maximum changes in lipids were largest in the humerus and
smallest in the tibia.
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Figure 2·4: Concentrations of (a) oxyhemoglobin, (b) deoxyhe-
moglobin, (c) water, (d) lipids, (e) total hemoglobin, and (f) tissue
oxygen saturation for the humerus (orange), femur (blue), and tibia
(green). The width of each violin is scaled by the number of obser-
vations in that bin and inside is a box plot, with the median (white
dot), interquartile range (thick black line), and whiskers extending to
1.5 times the quartiles (thin black line).
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Table 2.3: Mean and absolute maximum changes for chromophore
values between left and right sides within an individual.
Humerus Femur Tibia
Mean |Max| Mean |Max| Mean |Max|
µ′s slope 0.1 2.0 0.0 0.4 0.0 1.0
µ′s amplitude 0.7 0.2 0.0 0.3 0.0 0.3
HbO2 (µM) -1.2 47.3 -0.6 26.3 -1.0 12.3
HHb (µM) 0.5 10.5 0.1 3.7 0.8 6.9
Water (%) -1.1 21 1.5 10.5 1.7 22.3
Lipids (%) -2.0 31.5 2.3 23.5 0.1 10.9
THC (µM) -0.9 36.8 -0.5 26.1 -0.2 14.8
StO2 -0.3 13.1 0.0 8.1 -1.7 16.3
Within an individual, differences between the humerus, femur, and tibia were also
compared. Statistical differences between bones were found most frequently in the
concentration of water. Of the 24 subjects, 19 had differences in water between the
humerus and tibia, and 15 had differences between the femur and tibia. Only 2 had a
statistical difference between the femur and humerus. While the tibia was most dif-
ferent in water concentration, all bones had some differences in lipid concentration.
The tibia and humerus were different for 13 subjects and the femur and tibia were
different for 9 subjects. The fewest differences were in deoxyhemoglobin. Nine sub-
jects had a difference between the femur and humerus. Five subjects had a difference
between the humerus and tibia, and 4 subjects had a difference between the femur
and tibia.
As shown in Figure 2·5, Pearson’s correlation coefficient was calculated for body
fat estimates from skin fold measurements and lipid concentration from DOSI mea-
surements. The humerus, femur, and tibia had a Pearson correlation coefficient 0.6
(p = 0.007), 0.6 (p = 0.01), and 0.7 (p = 0.001), respectively. The p-value indicates
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the probability of an uncorrelated system producing data set that has a Pearson cor-
relation at least as extreme as the one computed from the body fat estimate and lipid
concentration (Jones et al., 2001).
Figure 2·5: Linear correlation between body fat percentage (%) and
DOSI lipid concentration (%) for the (a) femur, (b) humerus, and (c)
tibia.
Optical properties and chromophore values for each bone were compared for adult
and pediatric populations. For most optical properties and chromophores, there are
no statistical differences between adult and pediatric populations. However, in the
humerus, there was a statistical difference between the adult and pediatric subjects
in the scattering slope. The tibia and femur both had statistical differences in de-
oxyhemoglobin and tissue oxygen saturation. The water concentration statistically
differed in the femur for adult and pediatric populations.
2.3.4 Longitudinal measurements
A 26 year old female was measured four times in two weeks, as shown in Figure
2·6. Three of the four measurements were at the same time of day. The mean and
standard deviation from the four measurements of oxyhemoglobin, deoxyhemoglobin,
water, lipids, total hemoglobin, and tissue oxygen saturation for the humerus was
43.4 (9.6) µM, 14.5 (2.6) µM, 13.5 (2.1) %, 30.0 (9.2) %, 58.0 (12.1) µM, and 74.7
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(1.7) %. For the femur, the chromophore concentrations are 48.3 (16.1) µM, 14.7
(3.2) µM, 17.6 (3.5) %, 20.5 (10.4) %, 63.0 (17.9) µM, and 75.6 (5.3) %. For the
tibia, the chromophore concentrations are 28.1 (5.4) µM, 10.8 (2.2) µM, 32.4 (12.8)
%, 24.0 (6.7) %, 38.8 (5.7) µM, and 71.9 (5.7) %, respectively.
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Figure 2·6: A 26 year old female measured on four separate days with
DOSI. Concentrations of (a) oxyhemoglobin, (b) deoxyhemoglobin, (c)
water, (d) lipids, (e) total hemoglobin, and (f) oxygen saturation are
shown for the femur (blue), humerus (orange), and tibia (green).
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The mean and maximum change from baseline for the longitudinal measurements
are shown in Table 2.4. The femur has the largest average and maximum changes
for the scattering slope and amplitude while the humerus has the least. For chro-
mophores, the largest mean and maximum change occurred in the same bone. The
greatest mean and maximum changes in oxyhemoglobin, deoxyhemoglobin, and total
hemoglobin concentration were in the femur, humerus, and femur respectively. The
smallest changes in hemoglobin concentrations were in the tibia. The changes for wa-
ter are the largest for tibia and the smallest for lipids. For lipids, the largest changes
are in the humerus and the smallest are in the femur. The femur has the largest
changes in tissue oxygen saturation and the smallest changes are in the humerus.
Table 2.4: Mean and absolute maximum changes from baseline in
optical properties and chromophore values between visits.
Humerus Femur Tibia
Mean |Max| Mean |Max| Mean |Max|
µ′s slope -0.2 0.2 -0.6 0.8 -0.2 0.4
µ′s amplitude 0.1 0.1 0.0 0.1 0.0 0.1
HbO2 (µM) -9.7 13.5 17 26.3 -1.8 2.9
HHb (µM) -2.8 3.8 -2.1 2.3 0.4 1.4
Water (%) 2.8 3.7 3.6 5.5 8.7 13
Lipids (%) 13.3 16.2 1.6 1.8 1 4.6
THC (µM) -12.5 17.3 15 24.3 -1.3 3.7
StO2 -0.3 1.4 8.6 13.3 -2.7 4.4
Left and right sides of the body was compared for each bone. On the first visit, the
humerus had statistical differences in scattering slope and amplitude, oxyhemoglobin,
water, lipids, and tissue oxygen saturation. The only statistical difference in the
tibia was scattering amplitude. The femur had no statistical differences in optical
properties or chromophores.
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Comparisons between bones were made for each visit. On the first visit, the
femur and humerus statistically differed in scattering slope, oxyhemoglobin, deoxy-
hemoglobin, lipids, and tissue oxygen saturation. The femur and tibia differed in
oxyhemoglobin, total hemoglobin concentration, and tissue oxygen saturation. The
humerus and tibia differed in scattering slope, oxyhemoglobin, lipids, and total he-
moglobin concentration. No bones differed from each other in scattering amplitude
of deoxyhemoglobin.
Chromophore concentrations were compared for different bones on different visits.
The tibia was the most similar from visit to visit, having only one statistical different
in deoxyhemoglobing between visits 2–3. The humerus statistically differed in lipid
and water concentrations over the visits. Lipid content differed once between days
2–3. Water concentration differed between visits 1–3, 1–4, 2–3, and 2–4. The femur
statistically differed in oxyhemoglobin and total hemoglobin between visits 1–2. The
femur also statistically differed in water concentration between visits, 1–2, 1–4, and
2–3. Tissue oxygen saturation statistically differed in the femur between visits 1–2,
1–3, 1–4, 2–3, and 2–4.
2.4 Discussion
This normal volunteer study provides the first DOSI measurements of the distal
humerus, distal femur, and proximal tibia. These results suggest that DOSI is capable
of measuring and characterizing bony tissues.
The bones measured in this study presented a large variation of chromophore con-
centrations between subjects and within subjects. Compared to literature values for
bony anatomic locations, the chromophore values in this study resemble chromophore
measurements of the manubruim (Sekar et al., 2015a).
Thus far, the only frequency-domain DOS bony measurements have been in the
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patella (Farzam et al., 2013) where water concentration was assumed to be 15%, and
the total hemoglobin concentration and tissue oxygenation was measured to be 18±4
µM and 65±9%, respectively. From those values, it can be calculated that oxyhe-
moglobin has a concentration of 11.7 µM and deoxyhemoglobin has concentration of
6.3 µM. The chromophore values for water, oxyhemoglobin, and deoxyhemoglobin for
the patella (Farzam et al., 2013) are all lower than the mean chromophore concentra-
tions measured in this study.
Another study used a diffuse optical time resolved transmittance system to mea-
sure chromophores for the proximal femur (trochanter), distal and proximal radius,
distal and proximal ulna, and calcaneous (Sekar et al., 2015b). Once again, chro-
mophore measurements are very different, even when comparing the proximal femur
to the distal femur. Of the bony locations measured in Sekar et. al., the proximal
ulna is most similar to chromorphores reported in Table 2.2. In general, the most
similar chromophore is water concentration (17.4% (Sekar et al., 2015b) compared
to 15.2%), while the lipid concentrations are much higher and the oxyhemoglobin,
deoxyhemoglobin, and total hemoglobin concentrations are lower than the results re-
ported in Table 2.2. Sekar et. al. included collagen and a background variable as
additional chromophores which could contribute to some of the differences.
Differing chromophore concentrations between bony locations reported in this
study (Table 2.2 and Figure 2·4) could be from measurements on different parts of
the bone or partial volume effects. For example, the partial volume effect could be
a reason why the tibia had the highest water concentration: water is one of the top
three components of bone (Gul-E-Noor et al., 2015) and the tibia is most shallow of
the bones measured. As another example, most shallow bone had the lowest lipid
concentrations. The humerus had the highest lipid concentrations which could be
from a greater subcutaneous lipid layer over the bone, or it could be from measuring
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over the bone shaft where the fatty bone marrow is stored.
Few studies report means and standard deviations for both sides of the body
or for variation within an individual over time. Generally speaking, the boniest
locations had the most symmetry within an individual. Statistically the humerus
and tibia are most different from each other. With the exception of tissue oxygen
saturation, standard deviations of chromophores for normal tissue were greater than
those reported for normal tissue in a 57 person breast cancer study (Cerussi et al.,
2006).
2.4.1 Limitations
There are several limitations in this study. For example, the distribution of enrolled
subjects was a potential limitation. Bone cancers predominantly affect children, how-
ever, minors only represented 12% of the enrolled subjects. While sample sizes are
small and there is variability in the data, more pediatric subjects would need to be
measured to know if there are differences in chromophore concentrations between the
populations. This study serves as the first documentation of the optical characteri-
zation of these sites.
The measurement locations are an additional potential limitation. Sarcomas are
diverse diseases that can form anywhere in the body. This study chose to focus on
three of the most common anatomic locations that would be expected to present in
a clinical setting—the distal humerus, distal femur, and proximal tibia account for
66% of osteosarcoma locations (Bielack et al., 2002). While measurement points are
aligned to bones and bony landmarks, the bone depth and underlying tissue structure
is unknown for the normal volunteers. Measurements on the humerus and the tibia
were taken at an absolute distance from a bony landmark on all volunteers (Section
2.2.3) and differences in height and bone length could cause measurement locations
to be on different parts of the bone or on different vascular beds (Meertens et al.,
27
2018). Reported optical properties and functional information are an averaged value
for the underlying tissues including the tissue of interest (bone).
The next potential limitation includes the choice of chromophores for this work.
For this investigation, oxyhemoglobin, deoxyhemoglobin, water, and lipids were fit
to measured broadband absorption spectra. In muscular area, myoglobin is a likely
contributor to absorption. However, the spectra for myoglobin and hemoglobin are so
similar they cannot be separated in this context (Chance et al., 1988). Collagen is also
an important component in bone, tendon, cartilage, muscle, and skin (Lodish et al.,
) and several groups have added collagen to their fitting procedures (Pifferi et al.,
2004; Zhao et al., 2017; Taroni et al., 2007; Sekar et al., 2015a; Sekar et al., 2015b).
The use of collagen as a contributing absorber is relatively recent, and there are
limited experimental methods to validate the accuracy of collagen fits. For example,
there are no known reports demonstrating the fabrication of tissue mimicking optical
phantoms that incorporate collagen at physiologically relevant concentrations at the
volume scales needed for diffuse optical measurements. These reasons contributed
to the decision not to include collagen in this work. If collagen was included as a
chromophore, the lipid, water, and deoxyhemoglobin concentrations reported in this
study would decrease (Taroni et al., 2007).
An additional potential limitation involves the use of the specific light propaga-
tion model. In this work, the P1 diffusion approximation of the Boltzmann transport
equation was used. This model assumes a homogeneous optically diffusive media,
and the specific boundary conditions used for solving the analytical diffusion equa-
tion assume a semi-infinite media (Haskell et al., 1994; Pham et al., 2000). It has
not been validated that in vivo measurements of bone, which is porous and highly
structured, meet these criteria. It is notable that available NIR absorption spectra
of bone indicate that reduced scattering is at least an order of magnitude larger than
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absorption, providing support that bone is an optically diffusive media (Pifferi et al.,
2004). In vivo measurements, however, involve multiple chromophores, layered tissue,
and complex microarchitecture.
2.4.2 Conclusions
This study demonstrated the ability of DOSI to measure optical properties and func-
tional information at the distal femur, distal humerus, and proximal tibia. DOSI was
able to measure healthy tissue, although there was substantial variation among sub-
jects and within subjects. Going forward, technological developments to the probe
design would facilitate measurements at these anatomic locations.
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Chapter 3
Determine if DOSI can detect differences
between normal and sarcoma tissue
3.1 Introduction
DOSI has not been used previously to evaluate sarcomas. These tumors present sev-
eral challenges due to the varied anatomic locations where they develop, their depth
within tissue, and the substantial differences in tissue composition compared to breast
tissue. The goals of this work are to establish that sarcomas can be measured in a
variety of anatomic locations, and to quantify DOSI performance for these measure-
ments, including signal levels and imaging depth. Due to the rarity of this disease,
these initial measurements represent a crucial step in laying the groundwork for future
studies of this patient population, and point towards improvements in DOSI technol-
ogy likely needed to achieve optimal results. The work presented in this chapter is
based on manuscript published by H.M. Peterson, B.H. Hoang, D. Geller, R. Yang,
R. Gorlick, J. Berger, J. Tingling, M. Roth, J. Gill, and D. Roblyer in “In vivo, non-
invasive functional measurements of bone sarcoma using diffuse optical spectroscopic
imaging”, Journal of Biomedical Optics, December 2017.
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3.2 Methods
3.2.1 Subject eligibility and enrollment
All subjects currently diagnosed with a sarcoma and scheduled to undergo neoad-
juvant chemotherapy were eligible. Pregnant females were excluded from the study.
Informed consent was obtained from all subjects. Minors (<18 years) gave assent
to the best of their ability to understand, and their parent or guardian gave written
informed consent. This project was approved by the Institutional Review Boards at
Boston University and Montefiore Medical Center.
3.2.2 DOSI instrumentation
The DOSI system used for this study is the same as described in Section 1.2.1.
The system is compact and fits on a medical cart, allowing bedside access during
chemotherapy. All measurements for this study were taken with a source-detector
separation of 28 mm.
3.2.3 Imaging procedures
The measurement procedure used is the same as Section 2.2.3. However, instead of
four point measurements, a grid of fiducial markers with 1 cm spacing was transferred
onto the skin surface overlying or immediately adjacent to the underlying tumor
using a transparency and nonpermanent surgical marker. The transparency included
landmarks to identify the same region of interest for any subsequent measurements
and to identify the DOSI measurement location on the MRI. An operator scanned
the handheld probe over the grid, taking a point measurement at each location.
A single point measurement typically took 15 to 30 s, which includes the time it
takes to position the probe, ensure good contact between the probe and the skin,
and acquire data. After processing the data using the methods described in Section
31
1.2.2, a 2-D map of chromophore values is created by a linear interpolation between
measurement points. A typical measurement area for this study contained an average
of 35 individual point measurements on both the tumor and on the contralateral
normal tissue.
3.2.4 Estimates of signal-to-noise ratio
The experimental signal-to-noise ratio (SNR) was calculated as the raw amplitude
divided by a dark measurement. The dark measurement was calculated as the average
of five measurements taken on a highly absorbing black phantom. The SNR was
calculated for all measurements. For each subject, the median SNR and 10 to 90
percentile range are reported from the average SNR of all measurements as a function
of the modulation frequency.
3.2.5 Data quality
To be included in the dataset, the 90th percentile of the SNR needed to be greater
than 3 for three of the four lasers. It was determined that under this threshold,
data were not of sufficient quality for accurate optical property extraction. This
requirement ensures that there are at least three data points for the power law fit of
µ′s. If the SNR did not meet this condition, the subject was excluded from analysis.
3.2.6 Estimates of tumor depth
All subjects had at least one MRI before the start of treatment. A bone landmark
near the DOSI measurement site, clearly identifiable by the operator during the DOSI
measurement as well as on the corresponding MRI, was used to correlate DOSI mea-
surement regions on the patient’s MRI. More specifically, the distance from a bone
landmark to a specific DOSI measurement location was recorded on the DOSI trans-
parency. Using the subject’s most recent MRI before the start of treatment, this
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distance was measured from the same bone landmark along the surface of the skin
using the ruler tool in Centricity Enterprise Web (General Electric Company, Chicago,
Illinois). Once the DOSI measurement location was found on the MRI, the ruler tool
was used to measure the distance perpendicular from the surface of the skin to the
edge of the tumor margin, providing an estimate of tumor depth.
3.2.7 Estimates of imaging depth
DOSI imaging depth was estimated from the photon hitting density (PHD) deter-
mined at a line perpendicular to the tissue surface emanating from the geometric
midpoint between the source and detector locations. The peak PHD and the 90%,
50%, and 10% of the peak PHD are also recorded. A visual representation of the
imaging depths is shown in Figure 3·1. The PHD was calculated based on the defini-
tion described by Schotland et al., (Schotland et al., 1993) using the Virtual Photonics
Simulator (Virtual Photonics Initiative, Irvine, California) with the analytic solution
to the standard diffusion approximation and assuming a homogenous media and an
isotropic point source. Simulation optical properties were determined from the optical
properties of a DOSI measurement that was colocated with MRI for each subject.
3.2.8 Comparison of optical properties and chromophore concentrations
The two-sided Mann-Whitney test was used to statically compare the distribution of
point measurements for tumor and contralateral normal tissue using SciPy 1.0.0 in
Python version 2.7.13 (Python Software Foundation, 2015; Jones et al., 2001).
3.2.9 Longitudinal measurements
Subjects were measured at tumor and contralateral normal locations throughout
neoadjuvant chemotherapy treatment. Time points of interest include baseline (before
treatment), early in treatment, neoadjuvant treatment midpoint, and before surgery.
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Figure 3·1: DOSI imaging depth estimates from the PHD. At a line
perpendicular to the tissue surface emanating from the geometric mid-
point between the source and detector locations (red dotted line), the
peak PHD (black dotted), and the 90%, 50%, and 10% of the peak PHD
(black dash-dot, dashed, and solid lines, respectively) are calculated.
The inset shows the PHD profile along the midline.
The two-sided Mann-Whitney test was used to statically compare the distribution
of point measurements for tumor and contralateral normal tissue at each time point
using SciPy 1.0.0 in Python version 2.7.13 (Python Software Foundation, 2015; Jones
et al., 2001). The two-sided Mann-Whitney test was also used to statically compare
the distribution of point measurements for tumor and contralateral normal tissue be-
tween time points. At each time point, the mean tumor to contralateral normal ratios
for functional hemodynamic were calculated.
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3.3 Results
3.3.1 Subject enrollment and tumor characteristics
Nine subjects diagnosed with osteosarcoma (n=6), Ewing’s sarcoma (n=2), or round
cell sarcoma (n=1) were enrolled in the study. Subjects are identified with a four digit
identifier, the first being designated as 1001, the second as 1002, etc. The subject and
tumor characteristics of the nine subjects are shown in Table 3.1. Locations measured
were the femur (n=3), tibia (n=3), humerus (n=1), ribs (n=1), and calf (n=1).
Three subjects were excluded from analysis. For one subject diagnosed with os-
teosarcoma of the distal femur, the tumor location was too sensitive to touch and
therefore could not be measured with DOSI. For two other subjects both diagnosed
with osteosarcoma of the proximal tibia, the DOSI signal was determined to be too
low for analysis, likely because of a highly attenuating tumor. Of the remaining six
subjects, five were measured with DOSI before neoadjuvant chemotherapy and one
was measured on the 9th day of treatment. Of the six subjects included in the anal-
ysis group, five were determined to have a good pathologic response to neoadjuvant
chemotherapy, and one had a poor response.
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Table 3.1: Subject and tumor characteristics.
Group
Variable Analysis Excluded All
Subjects 6 3 9
Age (median and range (years)) 12 [9–19] 16 [14–30] 14 [9–30]
Sex
Male 5 3 7
Female 2 0 2
Race
White 2 0 2
Black/African-American 0 2 2
Hispanic 4 0 4
Other 0 1 1
Site
Trunk 1 0 1
Extremity 5 3 8
Location
Left 4 0 4
Right 2 3 5
Disease
Osteosarcoma 3 3 6
Ewing’s sarcoma 2 0 2
Round cell sarcoma 1 0 1
Median tumor depth (mm) 9.70 5.15 9.40
Percent necrosis (median and range (%)) 97 [85–99] 80 [30–95] 95 [30–99]
Pathologic response
Good 5 1 6
Poor 1 2 3
Mean number of DOSI
data points at baseline
73 64 70
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3.3.2 Estimates of signal-to-noise ratio at baseline
For subjects 1004, 1006, and 1007, poor SNR was achieved at higher modulation
frequencies so data was processed from 50–300 MHz. For all subjects, the frequency
domain data taken at the shortest wavelength, 659 nm, had the lowest SNR while
data taken at 781 nm had the highest SNR, as seen in Table 3.2. For the frequency
domain data taken at 659 nm, the median SNR and 10–90 percentiles for subjects
1001, 1002, 1004, 1005, 1006, 1007, 1008, and 1009 were 82 [29, 149], 41 [13, 68], 9
[3, 11], 2 [1, 2], 6 [3, 8], 12 [6, 15], 19 [8, 31], and 2 [1, 2] respectively. The median
SNR taken at 781 nm were 296 [118, 441], 165 [71, 247], 58 [41, 68], 16 [11, 20], 59
[38, 74], 67 [48, 79], 99 [44, 145], and 24 [17, 29] respectively for subjects 1001, 1002,
1004, 1005, 1006, 1007, 1008, and 1009.
Table 3.2: Median SNR with 10–90 percentiles from average SNR of
all measurements.
Wavelength (nm)
Subject 659 689 781 829
1001 82 [29, 149] 89 [37, 152] 296 [118, 441] 162 [56, 390]
1002 41 [13, 68] 44 [18, 75] 165 [71, 247] 108 [37, 233]
1003 † † † †
1004 9 [3, 11] 13 [9, 17] 58 [41, 68] 41 [20, 67]
1005 2 [1, 2] 3 [2, 3] 16 [11, 20] 15 [8, 26]
1006 6 [3, 8] 10 [6, 13] 59 [38, 74] 46 [23, 81]
1007 12 [6, 15] 19 [13, 24] 67 [48, 79] 39 [21, 64]
1008 19 [8, 31] 28 [12, 47] 99 [44, 145] 51 [19, 110]
1009 2 [1, 2] 3 [2, 4] 24 [17, 29] 20 [11, 36]
† DOSI measurement not taken
Tables 3.3 and 3.4 compare the SNR for contralateral normal tissue and tumor
measurements. Tumor measurements had a lower SNR compared to the contralateral
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normal measurements for all wavelengths for subjects 1002, 1005, 1007, and 1009.
With the exception of SNR measurements at 658 nm, tumor measurements had a
lower SNR for subjects 1001 and 1004. For subjects 1006 and 1008, the SNR for
tumor and contralateral normal tissues are similar.
To be included in the dataset, the 90th percentile of the SNR must be greater than
3 for three of the four lasers (Section 3.2.5). However, for subjects 1005 and 1009,
the tumor measurements did not meet this threshold (Table 3.4), and the subjects
were excluded from further analysis.
Table 3.3: Median SNR with 10–90 percentiles from average SNR of
contralateral normal measurements.
Wavelength (nm)
Subject 659 689 781 829
1001 77 [28, 134] 91 [40, 146] 316 [132, 454] 177 [63, 417]
1002 43 [14, 72] 47 [19, 79] 179 [77, 267] 116 [39, 250]
1003 † † † †
1004 10 [3, 12] 15 [10, 19] 63 [44, 74] 44 [22, 73]
1005 2 [1, 2] 3 [2, 4] 20 [13, 26] 19 [10, 35]
1006 6 [3, 8] 10 [6, 13] 58 [38, 72] 44 [23, 77]
1007 16 [8, 20] 24 [16, 30] 86 [62, 103] 50 [27, 83]
1008 18 [8, 30] 28 [11, 46] 99 [44, 147] 51 [18, 114]
1009 2 [1, 3] 5 [3, 6] 36 [25, 43] 30 [16, 54]
† DOSI measurement not taken
3.3.3 Estimates of tumor and imaging depths at baseline
The tumor depth for each of the subjects as determined by MRI is shown in Table
3.5. The peak intensity of the PHD halfway between the source and detector was
calculated as 5.8, 5.6, 4.5, and 5.5 mm for subjects 1001, 1002, 1004, and 1006
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Table 3.4: Median SNR with 10–90 percentiles from average SNR of
tumor measurements.
Wavelength (nm)
Subject 659 689 781 829
1001 86 [30, 161] 88 [35, 156] 279 [108, 430] 149 [51, 368]
1002 39 [13, 65] 42 [17, 71] 152 [65, 227] 101 [35, 215]
1003 † † † †
1004 8 [3, 9] 12 [8, 14] 52 [37, 62] 38 [19, 61]
1005 2 [1, 2] 2 [2, 3] 12 [9, 13] 10 [6, 16]
1006 6 [3, 8] 10 [6, 13] 60 [38, 76] 47 [24, 85]
1007 8 [4, 10] 14 [10, 18] 48 [35, 56] 27 [15, 45]
1008 19 [8, 31] 28 [12, 47] 98 [44, 142] 50 [19, 107]
1009 1 [1, 1] 2 [1, 2] 12 [8, 15] 10 [5, 16]
† DOSI measurement not taken
respectively. As seen in Table 3.5, the estimated peak intensity of the PHD does not
reach the tumor for any of the measured subjects. The 50% of the peak PHD was
calculated as 12.8, 11.4, 9.8, and 10.8 mm for subjects 1001, 1002, 1004, and 1006
respectively. The 50% of the peak PHD reaches the tumor for subjects 1001 and 1002.
For subject 1004, the 50% of the peak PHD is beyond the layer of subcutaneous fat
but not within the tumor. However, for three of the four tumors included in the
analysis group, 10% of the peak PHD reached the tumor, suggesting some photons
are probing the tumor tissue. For subject 1006, the depth at 10% of the peak PHD
is within the subcutaneous fat layer.
3.3.4 Optical properties at baseline
Optical properties were compared for measurements taken on the tumor and con-
tralateral normal tissues for each subject (Figures 3·2 and 3·3). The median and
interquartile ranges in Figures 3·2 and 3·3 show a high degree of variability between
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Table 3.5: Tumor and imaging depths.
Subject
Variable 1001 1002 1003 1004 1005 1006 1007 1008 1009
Tumor
depth (mm)
5.89 9.40 9.85 9.99 5.15 32.23 7.80 26.70 1.90
Subcutaneous
fat thickness (mm)
5.89 5.70 4.46 4.64 5.15 25.04 6.10 11.70 1.90
Imaging depth
in tumor (mm)
Peak intensity 5.8 5.6 † 4.5 ‡ 5.5 4.90 5.8 ‡
90% of the
peak PHD
21.4 18.0 † 15.5 ‡ 16.6 16.1 18.4 ‡
50% of the
peak PHD
12.8 11.4 † 9.8 ‡ 10.8 10.3 11.7 ‡
10% of the
peak PHD
8.2 7.6 † 6.3 ‡ 7.4 6.8 7.9 ‡
† DOSI measurement not taken
‡ DOSI measurement not processed
subjects and within subjects, and the shape of the absorption and the reduced scat-
tering coefficient spectra differ substantially between subjects. Between subjects, the
differences in absorption magnitude may be caused by differences in intrinsic prop-
erties, tumor size, or tumor depth (Figure 3·2). Within subjects, there are clear
differences between tumor and contralateral normal tissues, especially in subjects
1001, 1004, and 1007 (Figure 3·2a, 3·2c, and 3·2e respectively). Subjects 1002, 1006,
and 1008 have subtle spectral differences between tumor and normal tissue, with the
strongest differences appearing in absorption spectra near 980 nm.
There are statistical differences between tumor and contralateral normal scattering
amplitude for subject 1001 (p = 0.004) and 1007 (p <0.001). There are statistical
differences in scattering slope for subjects 1001 and 1007 (p <0.001 and p <0.001
respectively). The scattering slope and amplitude appear different for subject 1004
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but the p-values are not statistically different (p = 0.051 and p = 0.110). In subjects
1002, 1006, and 1008 the scattering amplitude and slope are not statistically different
(p = 0.512 and p = 0.674 for subject 1002, p = 0.830 and p = 0.888 for subject 1006,
and p = 0.290 and p = 0.341 for subject 1008). Subjects 1002, 1006, and 1008 all
have osteosarcoma of the distal femur.
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Figure 3·2: Median (solid line) and interquartile range (shaded) of µa
versus source wavelength obtained at tumor (blue) and contralateral
normal (dark blue) locations for six sarcoma patients (a–f).
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Figure 3·3: Median (solid line) and interquartile range (shaded) of µ′s
versus source wavelength obtained at tumor (blue) and contralateral
normal (dark blue) locations for six sarcoma patients (a–f).
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Figure 3·4: A 10 year old male with osteosarcoma in the right distal
femur was measured with DOSI before neoadjuvant chemotherapy. (a)
Diagram of bones in the right knee. The measurement area is the
shaded region with the origin being the bottom tip of the patella. (b)
Oxygen saturation maps for tumor and contralateral normal tissue.
3.3.5 Chromophore concentrations at baseline
There are differences in chromophore concentrations between tumor and contralateral
tissue for all subjects in the analysis group. For example, Figure 3·4 shows a DOSI
measurement of subject 1002 taken prior to neoadjuvant treatment. The measurement
area, shown in Fig. 3·4a, was a “T” shape with a 1 cm spaced grid containing 48
points that covered a 7 x 7 cm area. For this region of interest, the total DOSI
measurement time was 24 min. Despite the fact that 50% of the peak PHD did
not reach the tumor (Table 3.5), oxygen saturation maps reveal differences between
normal and sarcoma tissue, as seen in Fig. 3·4b (p <0.001). There is a strong visible
correlation between oxygen saturation and tumor location, especially at the most
superficial bone locations.
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Figure 3·5: Hemoglobin concentrations (µM) for tumor (blue) and
contralateral normal (dark blue) tissue for six sarcoma subjects (a–f).
? represent a statistical significance between tumor and contralateral
normal tissue at p = 0.05.
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Figure 3·6: Water, lipid, and oxygen saturation (% concentration)
for tumor (blue) and contralateral normal (dark blue) tissue for six
sarcoma subjects (a–f). ? represent a statistical significance between
tumor and contralateral normal tissue at p = 0.05.
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Chromophore information is summarized for each subject analyzed in Figures 3·5
and 3·6. As shown in Figure 3·5, tumor and contralateral normal tissue statistically
differed in total hemoglobin concentration for five of the six subjects (p <0.001, p
<0.001, and p = 0.035, p <0.001, and p = 0.013, for subjects 1001, 1004, 1006, 1007,
and 1008, respectively).
Subjects 1002, 1004, 1007, and 1008 had a higher median total hemoglobin concen-
tration in the tumor compared to the contralateral normal, whereas subjects 1001 and
1006 had the opposite trend. For subject 1001, differences in total hemoglobin were
driven by deoxyhemoglobin (p <0.001). For subjects 1004, 1006, and 1007, both de-
oxyhemoglobin (p <0.001, p = 0.037, and p <0.001, respectively) and oxyhemoglobin
(p = 0.007, p = 0.038, and p <0.001, respectively) contributed to differences in to-
tal hemoglobin concentration. Subject 1008 has a statistically higher oxyhemoglobin
concentration in the tumor compared to the contralateral normal tissue (p = 0.003).
Oxygen saturation was higher in the tumor compared to the contralateral normal
tissue for subjects 1001, 1002, 1007, and 1008 (p <0.001 for all). For subjects 1004
and 1006, oxygen saturation is about the same or lower in the tumor (p = 0.643 and
p = 0.057, respectively). At the end of neoadjuvant treatment, subjects 1001, 1002,
1007, and 1008 also had a good response to treatment (>90% tumor-cell necrosis).
As seen in Figure 3·6, lipid concentrations were lower in tumor tissue compared
to contralateral normal tissue for four of the six subjects (p <0.001, p = 0.015, and p
= 0.001, and p <0.001 for subjects 1001, 1002, 1004, and 1007, respectively). Water
concentrations varied greatly between subjects. The median water concentration was
higher in tumor tissue compared to contralateral normal tissue for all except sub-
ject 1006. However, only subjects 1004 and 1007 had statistical differences in water
concentration (p <0.001 for both). Subjects 1004 and 1007 also had a substantially
higher water concentration in both tumor and normal tissue compared to the other
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subjects.
The Tissue Optical Index (TOI) is a commonly used contrast function in DOSI
breast cancer measurements (Cerussi et al., 2006; Tromberg et al., 2016). TOI is
defined as deoxyhemoglobin*water/lipids, it has been used to identify tumor location
(Cerussi et al., 2006). For subjects 1001, 1004, and 1007, the TOI is statistically
different between tumor and contralateral normal tissue (p <0.001 for all subjects).
This difference in TOI is not present for subjects 1002, 1006, and 1008.
3.4 Comparison of baseline sarcoma measurements to nor-
mal volunteers
Of the 9 sarcoma subjects measured in Chapter 3, 7 had a sarcoma in a location
measured in the normal volunteer study in Chapter 2. In general, the chromophore
concentrations are similar between the sarcoma subjects (Figures 3·5 and 3·6) and
the normal volunteers (Figure 2·4). Normal volunteers and sarcoma subjects were
measured with the same detector and hand held probe, but different instrumentation
systems, which could be a source of bias when comparing across populations.
All sarcoma subjects had a substantially higher lipid concentration than the nor-
mal volunteers. With the exception of subject 1001, all sarcoma subjects also had a
higher water concentration than the normal volunteers.
Subject 1001 had Ewing’s sarcoma at the humerus. The oxyhemoglobin, total
hemoglobin, and tissue oxygen saturation values were below one standard deviation
of the average from the volunteer study. For deoxyhemoglobin concentrations, the
contralateral normal tissue was within one standard deviation of the volunteer study
while the tumor tissue was below.
Subjects 1002, 1006, and 1008 all had osteosarcoma of distal femur. Compared
to the normal volunteer femur data, all contralateral normal tissue and the tumor
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for subject 1006 was more than one standard deviation outside the mean for tissue
oxygen saturation; the tumors for subjects 1002 and 1008 were inside one standard
deviation of the normal volunteer mean. Tumor and contralateral normal tissues had
oxyhemoglobin concentrations within one standard deviation of volunteer femur data
for subjects 1006 and 1008, while subject 1002 was outside one standard deviation.
For deoxyhemoglobin concentration, subject 1008 was inside one standard deviation,
subject 1006 was outside one standard deviation, and the contralateral normal side
of subject 1002 was inside while the tumor was outside one standard deviation. For
total hemoglobin concentration, subject 1006 and the tumor side of subject 1008 were
within one standard deviation while subject 1002 and the contralateral normal side
of subject 1008 was outside.
Of the normal volunteers, 64% had statistical differences between the left and
right distal humerus tissue. The magnitude of the chromophore differences at the
humerus between tumor and normal tissue is similar to differences between left and
right tissues in normal volunteers. Tissue oxygen saturation had the most notable
difference between tumor and normal tissue (10.7% difference) compared to left and
right tissues (2.5% difference). Average absolute value differences for volunteers in
oxyhemoglobin, deoxyhemoglobin, and total hemoglobin concentration are 8.4, 2.0,
and 9.2 µM, respectively. Average differences for volunteers in water, lipids, and tissue
oxygen saturation are 2.6, 7.9, and 2.5 %, respectively. For subject 1001, differences
for in oxyhemoglobin, deoxyhemoglobin, and total hemoglobin concentration are 0.8,
3.2, and 3.9 µM, respectively, while differences in water, lipids, and tissue oxygen
saturation are respectively 0.7, 10.5, and 10.7 %.
Of the normal volunteers, 48% had statistical differences between left and right
distal femur tissue. The magnitude of the chromophore differences at the femur
between tumor and normal tissue is similar to differences between left and right
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tissues in normal volunteers. Average absolute value differences for volunteers in
oxyhemoglobin, deoxyhemoglobin, and total hemoglobin concentration are 6.8, 1.5,
and 7.7 µM, respectively. Average differences for volunteers in water, lipids, and tissue
oxygen saturation are 3.3, 5.2, and 3.3 %, respectively. For subjects 1002, 1006, and
1008, average absolute value differences for in oxyhemoglobin, deoxyhemoglobin, and
total hemoglobin concentration are 2.9, 0.4, and 3.0 µM, respectively, while differences
in water, lipids, and tissue oxygen saturation are respectively 1.9, 2.0, and 3.7 %.
In the longitudinal measurements, sarcoma subjects had more statistically dif-
ferent chromophore concentrations between measurement time points (Section 3.4.1)
than the normal volunteers (Section 2.3.4). In the volunteers, hemoglobin concen-
trations rarely statistically differed between measurements whereas sarcoma subjects
had many differences in hemoglobin concentrations between measurements.
Three subjects could not be measured with DOSI. For one subject, the tumor
location was too sensitive to touch. Tactile sensitivity will be a limitation of the
technology. For two other subjects both diagnosed with osteosarcoma of the proximal
tibia, the DOSI SNR was too low. Unfortunately, these subjects were nonresponders.
Normal volunteer measurements did not have low SNR at the tibia. It is possible
that some characteristic of the nonresponding tumor is causing the low signal.
3.4.1 Longitudinal monitoring
Six subjects were measured longitudinally. Subjects 1002, 1004, and 1006 had com-
plete longitudinal measurements including before neoadjuvant chemotherapy (base-
line), at midpoint of neoadjuvant treatment, and before surgery. Subjects 1007 and
1008 did not have measurements before surgery due to a change in surgery schedule
and device failure, respectively. Due to adverse weather delaying device transport to
Montefiore Medical Center, the first measurement for subject 1001 was shortly after
neoadjuvant chemotherapy started.
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Throughout the course of treatment, the ratio of chromophore values between
tumor and contralateral normal tissue varied, as seen in Figure 3·7. At baseline and
early in treatment, subjects 1004, 1006, 1007, and 1008 had statistically different
oxyhemoglobin concentrations between tumor and contralateral normal tissue (Fig-
ure 3·5). As treatment progressed, all subjects had a decline in the mean tumor to
normal ratio of oxyhemoglobin (Figure 3·7a). Subjects 1004 (p = 0.007, <0.001, and
<0.001), 1006 (p = 0.038, <0.001, and <0.001), and 1007 (p <0.001 and p = 0.002),
had statistically different concentrations of oxyhemoglobin between tumor and con-
tralateral normal tissue throughout the course of treatment. At treatment midpoint,
oxyhemoglobin concentrations between tumor and normal tissue statistically differed
for subject 1001 (p <0.001), whereas for subject 1008, differences were no longer
present at treatment midpoint (p = 0.639). While there are fluctuations in the mean
tumor to normal ratio of oxyhemoglobin, subject 1002 had no statistical differences
in oxyhemoglobin concentration throughout the course of treatment.
Throughout the course of treatment, the mean tumor to normal ratio approaches
1 (Figure 3·7b). Subjects 1001, 1004, 1006, and 1007 had statistically different deoxy-
hemoglobin concentrations between tumor and contralateral normal tissue at baseline
and early in treatment (Figure 3·5). At treatment midpoint, statistical differences are
still present for subjects 1001, 1004, and 1006 (p <0.001, p <0.001, and p = 0.002,
respectively) but not subject 1007 (p = 0.341). At the end of treatment, subject
1004 had statistical differences between tumor and contralateral normal tissue (p =
0.001), but not subject 1006 (p = 0.080). Subjects 1002 and 1008 had no statisti-
cal differences in deoxyhemoglobin concentrations between tumor and contralateral
normal tissue throughout the course of treatment.
Total hemoglobin concentrations differed for all subjects between tumor and con-
tralateral normal tissue at baseline and early in treatment for all subjects except 1002
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(Figure 3·5). Subject 1002 had no statistical differences in total hemoglobin concen-
tration throughout the course of treatment. As seen in Figure 3·7e, for all other
subjects, total hemoglobin concentration differed between tumor and contralateral
normal tissue at every time point with the exception of subject 1008 at treatment
midpoint (p = 0.965).
At baseline and early in treatment, all subjects except 1006 and 1008 had a sta-
tistically lower lipid concentration in the tumor compared to contralateral normal
tissue (Figure 3·6). Subjects 1001 and 1004 had statistical differences between tumor
and contralateral normal tissue throughout the course of treatment (p <0.001, and p
<0.001 for subject 1001, and for p = 0.001, p <0.001, and p <0.001 for subject 1004).
There were no statistical differences in lipid concentration between tumor and normal
tissue at treatment midpoint for subject 1008 (p = 0.185) and the end of treatment
for subject 1002 (p = 0.145).
At baseline and early in treatment, only subjects 1004 and 1007 had a statistically
higher water concentration in the tumor tissue than the contralateral normal tissue (p
<0.001 for both, Figure 3·6). As seen in Figure 3·7c, at midpoint, normal tissue had
a higher water concentration than tumor tissue for all subjects except 1002 and 1007.
All subjects except 1007 had statistical differences between tumor and contralateral
normal tissue (p <0.001, p = 0.011, p <0.001, p <0.001, p = 0.341, and p <0.001
for subjects 1001, 1002, 1004, 1006, 1007, and 1008, respectively). At the end of
treatment, only subject 1004 had statistical differences in water concentration (p =
0.338, p <0.001, and p = 0.411, for subjects 1002, 1004, and 1006).
Subjects 1001, 1002, 1007, and 1008 had a statistical difference in tissue oxygen
saturation between tumor tissue and the contralateral normal tissue at baseline and
early in treatment (p <0.001 for all, Figure 3·6). At midpoint, subjects 1001, 1004,
1006, 1007, and 1008 had statistical differences in tissue oxygen saturation (p = 0.015,
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p <0.001, p <0.001, p <0.001, and p = 0.032, respectively). As see in Figure 3·7f, at
the final measurement, only subject 1006 had a statistical difference between tumor
and contralateral normal tissue (p <0.001).
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Figure 3·7: The mean tumor to contralateral normal ratio of (a)
oxyhemoglobin, (b) deoxyhemoglobin, (c) water, (d) lipids, (e) total
hemoglobin, and (f) tissue oxygen saturation for six sarcoma subjects.
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Comparing subsequent time points to the first measurement, all subjects had a
statistical differences in chromophore concentrations in both the tumor and the con-
tralateral normal tissue at their midpoint and final measurements. For subject 1001,
all chromophores were statistically for the tumor between the early in treatment and
treatment midpoint measurements except for lipids (p = 0.117 for lipids and p <0.001
for oxyhemoglobin, deoxyhemoglobin, total hemoglobin, water, and tissue oxygen sat-
uration). All chromophores were statistically different between measurements for the
contralateral normal tissue (p <0.001 for deoxyhemoglobin and total hemoglobin, p
<0.020 for oxyhemoglobin, water, and tissue oxygen saturation).
For subject 1002, deoxyhemoglobin concentrations at midpoint and before surgery
statistically differ from baseline for both tumor and contralateral normal tissue (p
<0.013). Tissue oxygen saturation differs at midpoint and before surgery in tumor
tissue and at midpoint for contralateral normal tissue (p <0.001 for all). Before
surgery, tissue oxygen saturation in contralateral normal tissue does not differ from
baseline (p = 0.447). Lipid concentration differs at midpoint and before surgery in
tumor tissue and at before surgery for contralateral normal tissue (p <0.005 for all).
Oxyhemoglobin, total hemoglobin, and water concentrations only statistically differ
from baseline before surgery (p <0.006 for both tumor and contralateral normal tissue
for all chromophores).
All tumor chromophore concentrations differ from baseline in subject 1004 except
for the lipid concentration before surgery (p <0.001 and p = 0.768, respectively).
In the contralateral normal tissue, the lipid concentration and tissue oxygen satura-
tion differed at treatment midpoint and before surgery (p <0.001 for all). Deoxy-
hemoglobin and water differed from baseline at treatment midpoint (p <0.001 and
p = 0.006, respectively) while oxyhemoglobin and total hemoglobin concentrations
differed before surgery (p = 0.021 and 0.043, respectively).
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At treatment midpoint and before surgery, oxyhemoglobin, deoxyhemoglobin, to-
tal hemoglobin, and tissue oxygen saturation statistically differed for both tumor and
contralateral normal tissue (p <0.002 for all). At treatment midpoint, the tumor
water and lipid concentration are different from baseline (p <0.001 and p = 0.044,
respectively). In the contralateral normal tissue, water concentrations differ from
baseline at midpoint and before surgery (p <0.001 and 0.006, respectively) and lipids
differ before surgery (p <0.001).
All tumor and contralateral normal tissue differed from baseline for subject 1007 (p
<0.005), except for oxyhemoglobin and total hemoglobin concentrations at treatment
midpoint (p = 0.752 and p = 0.607, respectively).
For subject 1008, oxyhemoglobin, deoxyhemoglobin, lipids, and tissue oxygen sat-
uration statistically differed between baseline and treatment midpoint for both tumor
and and contralateral normal tissues (p <0.015 for all). Water concentration in the
tumor differed (p = 0.005) but there were no statistical differences in total hemoglobin
concentration.
Analyses completed on a small region of interest did not change the trends, only
the magnitude of the trends. Similarly, the trends remained the same when comparing
the ratio of the medians instead of the means.
3.5 Discussion
This feasibility study presents the first measurements of optical properties and chro-
mophore concentrations of bone sarcomas using DOSI. In three of the nine enrolled
subjects, DOSI measurements could not be taken due to touch sensitivity (n = 1) or
could not be analyzed due to high tissue attenuation (n = 2). In the remaining six sub-
jects, DOSI measurements demonstrated contrast between tumor and contralateral
normal tissue in both optical properties and chromophore concentrations throughout
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neoadjuvant chemotherapy treatment. These results suggest that DOSI is capable of
measuring, monitoring, and characterizing sarcoma tumors, although improvements
in DOSI probe technology are needed to acquire accurate measurements in a larger
portion of this patient population.
The sarcomas measured in this study presented a diverse pattern of chromophore
concentrations. Despite this diversity, several commonalities were noted. For exam-
ple, three of the four subjects had statistically lower lipid concentrations in the tumor
compared with the contralateral normal tissue. Of these, subjects 1001, 1004, 1007
had the largest differences in tumor lipid concentration compared with contralateral
normal. Subjects 1001 and 1004 and both had Ewings sarcoma with a soft tissue
component and subject 1007 had round cell sarcoma in the calf. For these subjects,
the tumor may have displaced lipids content as it grew. Subject 1006 also had a soft
tissue component; however, there was no discernible difference in lipid concentration
between the tumor and contralateral normal side, likely because the tumor was so
deep (33.23 mm below the skin surface). It is also of note that the extracted lipid
concentrations for subjects 1001, 1002, 1006, and 1008 are higher than those previ-
ously reported for bony locations on the limbs, although these prior reports were from
more superficial locations (Pifferi et al., 2004).
While lipids were generally different in tumor compared with contralateral normal
regions, only subjects 1004 and 1007 had significantly different water concentrations
between tumor and contralateral normal tissue. It is of note that the magnitude of
the water concentration for subject 1004 was much greater than the other subjects,
and subject 1004 had the only measurement location not on the limbs (the tumor was
on the ribs). Subject 1007 is the only subject with a tumor in the muscle. Literature
values for water concentrations in tissue vary greatly (Taroni et al., 2007; Sekar et al.,
2015b; Pifferi et al., 2004) but with the exception of subjects 1004 and 1007, the water
57
concentrations in this study are similar to those previously reported for other bony
locations on the limbs.
Hemoglobin levels varied to a large extent over subjects, but the concentrations of
oxyhemoglobin and deoxyhemoglobin are generally comparable with other literature
values for bony tissue. (Sekar et al., 2015b; Sekar et al., 2015a; Farzam et al., 2013;
Pifferi et al., 2004; Doornbos et al., 1999) Median oxygen saturation values ranged
from 50% to 70%, which fall on the low end of values reported in literature for other
diffuse measurements performed on bone (Figure 3·6) (Sekar et al., 2015b; Farzam
et al., 2013; Farzam et al., 2014). It is of note that the bone measurements in this
study were not as superficial nor from the same locations as those in literature.
An interesting result from this study is that subjects 1001, 1002, 1007, and 1008
had a higher oxygen saturation in the tumor compared with the contralateral normal
tissue. Higher oxygen saturation could be from shunting or the increased metabolic
demand of the tumor (Vaupel et al., 1989). As a static measurement, DOSI cannot
distinguish differences between oxygen delivery and consumption, but adding a mea-
sure of blood flow may shed light on the specific physiology of these tumors (Cochran
et al., 2017). The TOI showed contrast between tumor and contralateral normal tis-
sue for the subjects with Ewings sarcoma. Both of these subjects had a soft tissue
component that was more superficial to the surface of the skin. The subjects without
TOI contrast had osteosarcoma of the distal femur.
Another exciting result is the statically different scattering slope for tumor and
contralateral normal tissue in subjects 1001, 1004, and 1007. These subjects have
Ewing’s sarcoma or round cell sarcoma. Small round cells is a hallmark feature of
these diseases (Bernstein et al., 2006). Scattering slope is correlated with differences
in particle size.
In this study, DOSI was also used to monitor changes in tumor and contralateral
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normal tissues over time. From baseline to before surgery, tumor chromophore concen-
trations trended towards contralateral normal concentrations, suggesting the tumor
tissue is becoming “normalized”. Chemotherapy is a systemic treatment and could
contribute to the changes measured in chromophore concentration within contralat-
eral normal tissue between measurements. Of the subjects measured longitudinally,
only subject 1004 was a nonresponder and there is nothing obviously different from
the longitudinal measurements (Figure 3·7). However, subject 1004 was one of two
subjects with Ewing’s sarcoma and the only measurement location not on the limbs
(the tumor was on the ribs). The percent necrosis at time of surgery was 85%, close
to the 90% threshold of good pathologic response.
For five of the nine subjects, tumor measurements had a lower SNR compared
to the contralateral normal measurements for all wavelengths. For subjects 1001
and 1008, tumor measurements had a higher SNR than contralateral normal tissue
at 659 nm. Subjects 1006 and 1008 have similar SNR for tumor and contralateral
normal tissues at all wavelengths, likely because the tumors were too deep to measure.
Due to low SNR, the DOSI instrumentation could not measure the majority of non-
responding tumors. It is likely these tumors where highly attenuating, but with
improved instrumentation, it is hoped that measurements will lead to a prognostic
marker.
3.5.1 Limitations
There were several notable limitations of this clinical study. First, due largely to the
rarity of the disease, the number of subjects is small and the anatomic sites measured
are diverse. For these reasons, the data shown serve as the first documentation of the
optical characterization of this patient population, but it is not possible to make gen-
eralized statements about sarcoma optical properties and chromophore concentrations
without more data.
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Imaging depth was a challenge for some bone sarcomas. Photons must travel
through skin, subcutaneous lipids, muscle, and bone to reach many of these tumors.
For four of the six subjects analyzed in this study, the tumor depth overlapped with
imaging depths (Table 3.5), but in two subjects, it is suspected that the tumor was
too deep to be measured with the current probe geometry (subject 1006, 32.23 mm
below the surface and subject 1008, 26.7 mm below the surface). Based on simulations
of PHD for subject 1006 using matched optical properties in this region, a source-
detector separation of 88 mm would be required for the 10% of the PHD peak to
reach the tumor margin, whereas the current probe used a 28-mm source-detector
separation. It is possible that the measured differences between tumor and normal
tissue for these subjects arose from inflammation or other peritumoral effects. To
better match tumor and imaging depths for cases like this, increased source-detector
separations could be implemented, transmission geometries could be explored, or the
use of late-photon gating could be used in time-domain systems to preferentially
emphasize the contribution of photons that have traveled more deeply.
Improvements in signal level would greatly assist for measurements in this patient
population. Tumors measured in the study had a large range of overall optical attenu-
ation, and for some subjects the measured hemoglobin concentrations were very high
(e.g., subject 1004 had an average tumor total hemoglobin level >70 µM), presenting
a challenge for achieving adequate SNR. In another subject (subject 1005), the SNR
was determined to be too low for accurate optical property extractions. Additionally,
if a larger source-detector separation were implemented to measure deeper tissues,
increased detector sensitivity would also be required to avoid low SNR. To increase
the SNR, larger area APDs or photomultiplier tubes (PMTs) could be utilized, but
each of these design choices involve tradeoffs. For example, larger area APDs gen-
erally have reduced modulation bandwidth, and PMTs have limited dynamic range
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and linear operating regions (Zhao et al., 2017).
Improvements to probe geometry and materials would also assist in measuring
this patient population. For example, subject 1003 could not be measured because
the tumor region was too tactile sensitive for a contact probe. A smaller probe
footprint or different, softer, probe materials may alleviate this, but it is possible
that subject tactile sensitivity could be a limitation of the technology for a portion
of this patient population. Additionally, while the majority of bone sarcomas form in
the long bones of the body (Bielack et al., 2002) sarcomas can form anywhere, and
the probe needs to accommodate a wide range of anatomic sites. A smaller probe
footprint or a flexible probe geometry may help facilitate measurements on angular
and bony surfaces. Additionally, larger source-detector separations may be necessary
to access deep tumors.
Additional limitations including the choice of chromophores and the light propa-
gation model have been previously discussed in Section 2.4.1.
3.5.2 Conclusions
Despite several potential limitations of this work, the data indicate that bone sarco-
mas are amenable to measurement with diffuse optical technologies and that optical
contrast exists between tumor and contralateral normal regions throughout the course
of treatment. Going forward, several key technological developments are required to
better measure this patient population, including more flexible probes and more sen-
sitive detection. Additionally, larger datasets are needed to characterize and quantify
sarcoma optical properties and treatment response dynamics.
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Chapter 4
Optimize DOSI instrumentation for
sarcoma
4.1 Introduction
In order to accommodate the angular, rigid, and highly attenuating bony tissues that
are common to sarcomas, the current DOSI instrumentation requires modifications.
This chapter focuses on the simulation, creation, and experimental validation of an
optimized DOSI probe that accurately measures common sarcoma locations.
4.2 Methods
4.2.1 Literature review of optical properties
To create physiologic simulations, an extensive literature review of optical properties
in the near-infrared wavelength range of 600–1000 nm for bone, muscle, and lipids was
conducted. As discussed in Section 1.2.4, there is limited information about diffuse
optics in bone. Due to the scarcity of available data, bone optical properties were
expanded to include a variety of bony anatomic locations.
The literature search for lipid optical properties included all tissues described as
having fat, adipose, or lipids. While breast tissue is a fatty tissue, it was excluded from
the literature review unless the paper specified “adipose” in the tissue description,
i.e. optical properties from “breast tissue” were excluded but “breast adipose tissue”
were included. Optical properties from intralipids were excluded because the choice
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of intralipid concentration was often not justified. Data from purified lipids were
excluded since they do not represent physiological concentrations. Two papers were
also excluded for failing to account for lateral light loss in their measurements which
may have lead to an overestimation of the absorption coefficient (Bashkatov et al.,
2011; Bashkatov et al., 2005). In addition, another paper was excluded as theirs were
the only samples that were hydrated with saline and sealed between a microscopic
slide and a coverslip (Salomatina et al., 2006).
The literature review specifically focused on optical properties at 658 nm, in hopes
of improving DOSI measurements at the wavelength with the lowest signal levels
(Subsection 3.3.2). Given the limited data at 658 nm, optical properties were pooled
from 630–670 nm. Due to the orders of magnitude variation, the median and 10 to
90 percentile ranges of µa and µ
′
s were calculated for fatty tissues, bone, muscle, and
combined bone-muscle for the pooled data.
For a full list of optical properties, please see Appendix A.
4.2.2 Selection of optical property test set
Frequency-domain DOSI does not directly measure optical properties—it measures
amplitude and phase (Pham et al., 2000). While high µa and µ
′
s values may be a
reason for low SNR, poor data quality may also stem from limitations in measuring
amplitude and phase.
Aware that optical properties may not linearly map to instrumentation space
(Erickson et al., 2010), the optical properties from Section 4.2.1 were used as inputs
to the forward simulation of the P1 approximation to calculate phase and amplitude.
The amplitude at 50 MHz from a calibrated measurement taken with a 28 mm source-
detector separation on a highly absorbing black phantom provided an estimate of the
amplitude noise floor.
Using data from Section 4.2.1, the median and 10 to 90 percentile range were
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combined in such a way to create the most extreme cases of optical property pairs
that might be seen in the clinic. Thus low scattering with high absorption and high
scattering with low absorption case studies were created. After plotting the phase
and amplitude in the forward stimulation, ten optical property pairs were chosen as a
test set for simulations and tissue-mimicking phantoms to test the dynamic range of
the DOSI instrumentation and validate the DOSI probe optimization. Among these
ten optical property pairs, some are expected to be quite easy to measure while others
will be impossible.
4.2.3 Creation of tissue-mimicking phantoms
Silicone tissue-mimicking phantoms were created using nigrosin as the absorbing agent
and titanium dioxide (TiO2) as the scattering agent. A 1.5g/L H2O nigrosin solution
was mixed into 600 mL of uncured silicone. Titanium dioxide and 60 mL of curing
agent were mixed and sonicated for 30 min before being blended into the silicone-
nigrosin mixture. The mixture was sealed in a vacuum chamber to remove air bubbles
before being poured into a mold. The phantom cures and hardens within the vacuum
chamber. For each phantom created, the quantities of nigrosin and TiO2 used are
shown in Table 4.1.
4.2.4 DOSI instrumentation
Poor optical SNR was a major limitation for the measurement of sarcoma (Section
3.3.2). In order to address this limitation, the BOTLab identified an APD with
a larger 3-mm active area (S11519-30-Hamamatsu Photonics, Hamamatsu, Japan).
The DOSI system used to test and validate the APD is the same system used in
Chapter 2.2.2. The amplitude modulated light is detected by either the APD with a
1-mm active area (C5658 with detector S-6045, Hamamatsu Photonics, Hamamatsu,
Japan) or with a 3-mm active area (S11519-30-Hamamatsu Photonics, Hamamatsu,
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Table 4.1: Tissue-mimicking phantom recipes.
Phantom Nigrosin (mL of 1.5g/L H2O solution) TiO2 (g)
all10 0.567 0.231
muscle10 1.368 0.274
bone10 0.453 0.325
all50 3.526 0.551
muscle50 7.204 0.166
bone50 0.772 1.540
bone90 3.085 2.682
bone1090-2 0.529 2.682
bone9010 2.956 0.565
muscle1090 1.322 3.008
bomat1 0.7 0.178
bone1090 0.453 6.790
hanphan1 0.877 0.711
hanphan2 0.628 0.255
Japan).
4.2.5 Calculation of signal-to-noise ratio
The experimental SNR was calculated the same way as the patient data SNR in
Section 3.2.4: the raw amplitude divided by a dark measurement using modulation
frequencies from 50–400 MHz. The dark measurement was calculated as the average
of five measurements taken on a highly absorbing black phantom. For each phantom,
the median SNR and the 10 to 90 percentile range is reported.
4.2.6 Calculation of accuracy and precision
The µa and µ
′
s values of on phantoms were measured with the 1-mm APD and 3-mm
APD. Bland-Altman plots tested the interchangeability of the detectors.
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The choice of calibration phantom may impact the calculation of optical prop-
erties. To inform the choice of calibration phantom, percent difference in optical
properties calibrated with ACRIN9 and INO9 were calculated using the 1-mm APD
at 22 mm source-detector separation.
4.2.7 Monte Carlo estimates of imaging depth
Imaging depth was estimated from maximum photon penetration depth. The max-
imum photon penetration depth was calculated as the maximum depth a collected
photon traveled during a simulation in the Monte Carlo Multi Layered tissue simula-
tor (MCML) (Calabro, 2013).
The simulation is a two layer model with the first layer mimicking subcutaneous
fat and the second layer a sarcoma-like tissue. Simulation optical properties were
determined from literature review (Section 4.2.1) and the sarcoma test set (Section
4.2.2). Given the wide range of µa values for fatty tissues, simulations were conducted
for a high (µa=0.013 mm
−1) and low (µa=0.003 mm−1) absorbing fatty tissue layer.
For both simulation conditions, the fatty layer was constant at µ′s=1.2 mm
−1. The
total simulation thickness remained constant at 100 cm with the first layer varying
from from 0 to 10 cm thick. The simulation launched photons until 10,000 photons
were collected or 48 hours passed and recorded the maximum penetration depth.
The numerical aperture (NA) of detection for the simulations was calculated with
the following equation
NA = n sin θ (4.1)
where n is the index of refraction of air at 658 nm (n =1) and θ is the angle of col-
lection (θ =56.3◦). θ was calculated using dimensions from the 3-mm APD datasheet
(Hamamatsu Photonics, ).
For each fatty layer thickness and sarcoma-like tissue, the proportion of photons
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reaching the underlying layer was calculated.
4.2.8 Optimal source-detector separation
One way to increase imaging depth is by increasing the source detector separation.
Using the sarcoma optical properties, the phase and amplitude were calculated at dif-
ferent source-detector separations using the forward simulation. As an experimental
validation, the sarcoma phantom set was measured with source-detector separations
from 34–88 mm. The SNR for each measurement was calculated using the methods
described in section 4.2.5.
4.2.9 Probe housing considerations
Improvements in the handheld probe geometry would assist in measuring the angular
and rigid anatomic locations common to sarcomas. The probe needs to accommo-
date a wide range of anatomic sites and have adequate contact on both sides of the
body while maintaining the same source-detector orientation. The source-detector
separation needs to be adjustable. In addition, the probe housing material must be
lightweight, temperature-insensitive (not cold or hot to the touch), and disinfectant
compatible. A preliminary probe housing was fabricated with ABS using 3D printing
to meet these criteria.
4.3 Results
4.3.1 Literature review of optical properties
Optical properties from literature review for bone, muscle, and lipid are show in Figure
4·1. Even with the expanded literature search to include bony locations, only nine
papers were identified citing µa and µ
′
s (including a paper citing results in Chapter
3). The 23 data points included in vivo and ex vivo measurements from six animal
sources (including humans) and fourteen different bony locations. Optical properties
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for muscle were reported in eleven papers; the 76 data points were from six animal
sources (including humans) for least eight different muscles. After removing papers
for quality control, ultimately seven papers with optical properties for lipids were
identified in the review, yielding 24 data points from three sources and six types of
lipids. A preliminary probe housing was fabricated to meet these criteria.
Figure 4·1: Literature values for µa (a) and µ′s (b) for lipid (gold),
muscle (green), bone (dark blue). Optical properties from 630–670 nm
used for further analysis are shaded in grey.
Given the scarcity of data and the variation of µa and µ
′
s values at 658 nm, optical
properties were pooled from 630–670 nm. The median and 10 to 90 percentile ranges
of µa and µ
′
s were calculated for fatty tissues, bone, muscle, and combined bone-
muscle for the pooled data and reported in Table 4.2. The median µa values for lipid,
muscle, and bone were respectively 0.110, 0.085, and 0.010 mm−1 and the µ′s values
were respectively 1.20, 0.66, and 1.29 mm−1. Values for µa ranged from 0.003 to 0.013
mm−1 for lipids, 0.016 to 0.16 mm−1 for muscle, and 0.007 to 0.036 mm−1 for bone.
Values for µ′s ranged from 1.17 to 1.26 mm
−1 for lipids, 0.42 to 3.08 mm−1 for muscle,
and 0.72 to 2.78 mm−1 for bone. For combined muscle and bone optical properties,
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µa ranged from 0.007 to 0.146 mm
−1 and µ′s from 0.43 to 2.85 mm
−1.
Table 4.2: Median and 10 to 90 percentile ranges of optical properties
from literature 630–670 nm.
Tissue µa (mm
−1) µ′s (mm
−1)
Lipid 0.011 [0.003, 0.013] 1.20 [1.17, 1.26]
Muscle 0.085 [0.016, 0.16] 0.66 [0.42, 3.08]
Bone 0.010 [0.007, 0.036] 1.29 [0.72, 2.78]
Muscle and bone 0.041 [0.007, 0.146] 0.83 [0.43, 2.85]
For a full list of optical properties used in analysis, please see Appendix A.
4.3.2 Selection of optical property test set
The literature review optical properties pairs from 630–670 nm were used as inputs to
the forward simulation of the P1 approximation to calculate the phase and amplitude
at 50 MHz with a 28 mm source-detector separation. As shown in Figure 4·2, when
plotted in the phase and amplitude space, lipid and muscle separate themselves along
the x-axis. With the 1-mm APD, 71.5% of the optical properties pairs fall below the
noise floor. The 3-mm APD has a lower noise floor than the 1-mm APD, potentially
allowing the measurement of an additional 43% of the optical property pairs from the
literature review.
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Figure 4·2: The phase and amplitude from the P1 diffusion approx-
imation of the radiative transport equation for optical properties in
literature from 630–670 nm for lipid (gold), muscle (green), bone (dark
blue), and sarcoma (blue) is shown. Black markers are the test set op-
tical properties defined in Table 4.3. The implementation of the 3-mm
diameter area detector will lower the noise floor (dashed line) and allow
a greater range of optical properties to be measured.
For simulations and experimental validation, ten optical property pairs (Table
4.3) were chosen as a test set. These optical properties span the phase and amplitude
space of the DOSI instrumentation. The following three optical property pairs (µa,
µ′s) are below the noise floor for both APDs: (0.016, 3.08), (0.036, 2.78), and (0.085,
0.66) mm−1. The following four optical property pairs are below the 1-mm APD’s
noise floor: (0.007, 2.78), (0.010, 1.29), (0.036, 0.72), and (0.041, 0.83) mm−1. Three
optical property pairs are above the noise floor for both APDs: (0.007, 0.43), (0.007,
0.72), and (0.016, 0.42) mm−1.
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Table 4.3: Optical property test set.
µa (mm
−1) µ′s (mm
−1) Marker
0.007 0.43 +
0.007 0.72 ◦
0.007 2.78 O
0.010 1.29 B
0.016 0.42 F
0.016 3.08 
0.036 0.72 ∗
0.036 2.78 4
0.041 0.83 ♦
0.085 0.66 ×
4.3.3 Signal-to-noise ratio
Compared to the 1-mm APD (C5658 with detector S-6045, Hamamatsu Photonics,
Hamamatsu, Japan), the 3-mm APD has a a 9-fold increase in active area for more
light collection. Testing has shown that the noise floor of the 3-mm APD is compa-
rable to 1-mm APD. As seen in Figure 4·3, the 3-mm APD has a higher SNR than
the 1-mm APD across all modulation frequencies.
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Figure 4·3: The SNR averaged across modulation frequencies for the
1-mm APD (dark blue) and the 3-mm APD (yellow).
Figure 4·4: Tissue-mimicking phantoms created from Table 4.1.
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Figure 4·4 shows the phantoms created in Section 4.2.3 and used to compare the
SNR. On average from 50–400 MHz, the 3-mm APD has a median SNR 18 times
greater then the 1-mm APD at a source-detector separation of 34 mm. For the
individual wavelengths 650, 690, 785, 808, 830, and 850 nm, the median SNR was 8,
12, 20, 16, 22, and 29 times greater, respectively. The 3-mm APD has a higher SNR
than the 1-mm APD and can measure more attenuating optical properties at longer
source-detector separations.
Figure 4·5: The median SNR at each wavelength for different source-
detector (SD) separations for a phantom for the 1-mm APD (blue, dark
blue, grey) and the 3-mm APD (yellow, orange).
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Figure 4·6: The median SNR at each wavelength for different source-
detector separations for a phantom for the 1-mm APD (blue, dark blue,
grey) and the 3-mm APD (yellow, orange).
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4.3.4 Accuracy and precision
Bland-Altman plots compared the difference and means of µa and µ
′
s from phantom
measurements using the 1-mm APD and the 3-mm APD in Figures 4·7 and 4·8,
respectively. For all wavelengths, measurements both µa and µ
′
s, the vast majority of
measurements lay within ±1.96 standard deviations. The largest deviations from the
average occur with increasing µa and µ
′
s values.
Thirteen phantoms with the 90th percentile of the SNR greater than 3 at 658 nm
were processed with the calibration phantoms ACRIN9 and INO9. Median percent
differences in µ′s were 2.5%, ranging from 1.1 to 4.4%. Percent differences in µa were
greater, the the median percent difference was 5.9% with a range from 2.8% to 15.2%.
Seven of the phantoms (54%) had <5% difference in µa values and four (31%) had
differences between 5–10%. The two phantoms that had the largest percent difference
were the phantoms with the smallest µa values.
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Figure 4·7: Bland-Altman plots comparing measurements of µa at
(a) 658, (b) 690, (c) 785, (d) 808, (e) 830, and (f) 850 nm. The mean
(solid line) and ±1.96 standard deviations (dashed lines) of the data
are shown.
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Figure 4·8: Bland-Altman plots comparing measurements of µ′s at
(a) 658, (b) 690, (c) 785, (d) 808, (e) 830, and (f) 850 nm. The mean
(solid line) and ±1.96 standard deviations (dashed lines) of the data
are shown.
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4.3.5 Estimates of imaging depth
MCML simulations estimated the photon imaging depth for sarcoma-like optical prop-
erties under a fatty layer. The proportion of photons that reach the underlying sar-
coma layer are shown in Figure 4·9.
Figure 4·9: Proportion of photons reaching an underlying sarcoma-
like tissue with varying lipid layer thicknesses. Simulations are for a
(a) low and (b) high absorbing lipid layer.
Both simulation situations had similar responses—50% of the photons reached
beyond a 0.8 cm lipid layer into the underlying tissue. In the low absorbing lipid
layer simulation, photons penetrated more deeply, with 50% of photons reaching
beyond a 1.4 cm lipid layer compared to a 1.2 cm lipid layer in the high absorbing
simulation. In the low absorbing simulation, 10% of photons passed beyond a lipid
layer of 1.6–2.4 cm thick and 90% passed a lipid layer 0.4–0.8 cm thick. In the high
absorbing simulation, 10% of photons passed beyond a lipid layer of 1.4–1.8 cm thick
and 90% passed a lipid layer 0.4–0.8 cm thick.
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4.3.6 Optimal source-detector separation
Simulations from the P1 diffusion approximation show that as the source-detector
separation increases from 22 to 40 mm, the amplitude approaches the noise floor of
the 1-mm and 3-mm APDs (Figure 4·10). Four test optical properties are above
the 1-mm APD noise floor at the shortest source-detector separation; in comparison,
there are nine above the 3-mm APD noise floor. At a source-detector separation of
40 mm, only one remains above the 1-mm noise floor compared to three above the
3-mm APD noise floor.
Figure 4·10: The phase and amplitude from the P1 diffusion approxi-
mation of the radiative transport equation for optical properties (µa,µ
′
s
(mm−1)) in sarcoma test set at 22 (gold), 28 (green), 34 (blue), and
40 mm (dark blue) source-detector separation. The noise floor for the
1-mm APD (solid line) and the 3-mm APD (dashed line) are shown for
reference.
The simulations in Figure 4·10 were validated experimentally with phantoms in
Figure 4·11. For all wavelengths, the SNR decreased as the source-detector separation
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increased. At the shortest source-detector separation, the 3-mm APD could measure
seven of the ten sarcoma-like phantoms at 658 nm (Figure 4·11a). However after 46
mm, the 3-mm APD could only measure three phantoms.
In Figure 4·11b, the SNR at 690 nm is greater, but after 52 mm, only three
phantoms could be measured. Figure 4·11c–f shows the SNR of wavelengths 785,
808, 830, and 850 nm are an order of magnitude greater than the SNR at 658 nm
(Figure 4·11a).
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Figure 4·11: 3-mm APD SNR for sarcoma-like phantoms at wave-
lengths (a) 658, (b) 690, (c) 785, (d) 808, (e) 830, and (f) 850 nm at
source-detector separations from 34–88 mm.
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4.3.7 Probe housing
The probe housing for the 3-mm APD was 3D-printed from ABS. The material is
lightweight, temperature-invariant, and disinfectant compatible. The source-detector
separation is adjustable and can be moved to either side of the APD housing. There
are many air holes for ventilation so the electronics do not overheat. The surface
area that comes into contact with the subject of handheld 3-mm APD probe is 66%
smaller than the 1-mm APD probe.
Figure 4·12: Designed probe housing for 3-mm APD.
4.4 Discussion
These simulations and experimental results are an important step towards measuring
sarcomas.
Optical properties from literature for bone, muscle, and lipid were quite diverse.
Values of µa and µ
′
s from 630–670 nm spanned an order of magnitude. Averaging
across an optical bandwidth of 40 nm and the diversity of biological samples, methods,
and instrumentation likely contributed to the wide range of values.
Sample preparations and measurements differed, which accounted for some of the
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variation in optical properties seen. Especially in muscle, sample preparations vastly
differed with samples being frozen, thawed, fresh, chopped, ground, or in vivo. For
muscle, this sample preparation appeared to affect scattering, with more “processed”
samples having lower µ′s values. In fatty tissues, fresh samples taken from surgery
and used within hours had the highest absorption, likely because water content was
still retained within the sample.
When comparing the choice of calibration phantom, the two phantoms that had
the largest percent difference in µa were the phantoms with the smallest µa values.
They were likely most affected by the optical property differences in the calibration
phantoms—at 658 nm, INO9 µa=0.008 mm
−1 whereas ACRIN9 µa=0.018 mm−1.
Given high absorbing tissues are the most likely to be encountered in a clinical setting,
ACRIN9 is the best choice for a calibration phantom.
As the laser wavelength with the worst SNR during volunteer and clinical mea-
surements (section 3.3.2), this chapter has used laser 658 nm as a benchmark for
improvements and optimization of the DOSI instrumentation. The 3-mm APD seems
like a promising detector to improve the SNR of the DOSI system. While the 3-mm
APD has a much larger surface area, the bandwidth is still broad enough that mea-
surements are not impacted. Not only does the 3-mm APD have a higher SNR across
all frequency ranges and optical property pairs, it can measure optical properties the
1-mm APD could not.
While 50% of photons reach 1 cm into tissue with the 1-mm APD at a 28 mm
source-detector separation, it would be beneficial to probe more deeply into tissues.
With the 3-mm APD, the SNR is higher at longer source-detector separations than
with the 1-mm APD. Based on the experimental results from Figure 4·11, source-
detector separations would be limited to <34 mm if choosing to optimize 658 nm.
However, this wavelength clearly struggles with such extreme optical property pairs,
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and it would be better not to include it. At 690 nm, half of the phantoms can be
measured with a source-detector separation of 40 mm. Repeating the simulations
from Section 4.3.5, 50% of photons would travel 0.5 cm deeper using a 40 mm source-
detector separation. In literature, diffuse optic probe source-detector spacing for bony
measurements ranged from 10–40 mm (Meertens et al., 2018).
From Figure 4·9, photons do not reach the underlying tissue with a lipid layer
thickness of 4 cm or more. If the tumor is below 1 cm or less of subcutaneous fat, 50%
of photons have a maximum depth within the tumor tissue. This supports the results
in Section 3.3.3 that photons are reaching the underlying tumor for the majority of
subjects. However, for tumors deeper than 2.5 cm of lipids, it is unlikely the detector
is measuring anything but subcutaneous fat at a source-detector separation of 28 mm.
In Chapter 3, subject 1006 showed contrast between tumor and contralateral nor-
mal tissue (Figures 3·2d, 3·3d, 3·5d, 3·6d) despite having a tumor 32.23 mm below the
surface of the skin (Table 3.5). While it is possible that a few far-reaching photons
contributed to the contrast, the PHD estimates and Monte Carlo simulations in Sec-
tions 3.3.3 and 4.3.5 show that it is unlikely. The contrast could be from peritumoral
effects surrounding the tumor, such as inflammation and edema, which may also be
important indicators of treatment response.
The smaller, symmetric probe footprint may facilitate access and adequate skin
contact to bony locations on both sides of the body while maintaining the same
source-detector orientation. To further decrease the contact area of the probe, the
detector could be fiber coupled. If the 3-mm APD was fiber coupled, the average
median SNR would only be 2 higher than the 1-mm APD. As shown in 4.3.3, the
3-mm APD has an average median SNR 18 time greater. A larger contact area was
kept in favor of the increased signal levels.
Another option would be to use a PMT instead of an APD. PMTs have a large
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active areas with a large dynamic range. However the BOTLab group has discovered
nonlinearites in dynamic range and signal level for several PMTs. Due to these non-
linearities, calibrations for each wavelength and each measurement would be required.
The additional calibrations would increase measurement time and the time necessary
with the subject. Using fiber coupled system, a separate PMT for each wavelength
could reduce the number of calibrations necessary, however, this solution still assumes
a linearity for each PMT over a wide range of optical properties.
4.4.1 Limitations
Bone is a complex and highly organized tissue with many components including cal-
cium, hydroxyapatite, collagen, marrow, cartilage, nerves, and blood (Lodish et al., ).
Values reported from DOSI measurements represent an average of the tissue, though
it is still unknown how the optical properties of bone change throughout the body
or from cancerous growth. Fatty tissue optical properties also vary with anatomic
location (Salomatina et al., 2006). Simulations tried to account for these variations
by running many simulations under a variety of optical property conditions.
A potential limitation is that simulations were not performed for the frequency-
domain. However, Binzoni et al. showed that for modulation frequencies <200 MHz,
frequency-domain and continuous wave measurements had equivalent depth sensitiv-
ities (Binzoni et al., 2017).
Another potential limitation is that the 3-mm APD needs more experimental
validation. While the Monte Carlo simulations agree with the depth estimates from
the PHD simulations in Section 3.3.3, they do not account for instrument response.
Experimental validation of the two-layer model is necessary to show that the 3-mm
APD measures deeper tissues.
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4.4.2 Conclusions
The simulations and experimental data indicate that the 3-mm APD will improve
measurements on more highly attentuating tissues at deeper imaging depths.
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Chapter 5
Conclusions
This project developed and validated DOSI as a non-invasive measurement modality
to track treatment for sarcomas.
5.1 Discussion
DOSI can measure several bony locations in normal volunteers. For the first time,
the optical properties and functional hemodynamic information of the distal femur,
tibia, and humerus were characterized in normal volunteers.
In this study, DOSI demonstrated the ability to measure optical properties and
functional information at several sarcoma locations throughout the course of treat-
ment. It was able to differentiate between healthy and sarcoma tissues within patients.
However, DOSI can currently only measure some sarcomas due to SNR issues.
An improved measurement setup with a larger area APD was able to increase
SNR. The 3-mm APD shows potentially promising results for measuring more atten-
uating tumors that are deeper within tissue. With the implementation of the 3-mm
APD in a handheld probe and a different selection of laser wavelengths, hopefully a
larger portion of the sarcoma population can be measured and characterized. In the
future, DOSI may provide a way to monitor treatment response and improve patient
outcomes.
Compared to breast cancer, sarcomas have highly variable anatomic sites and
chromophore concentrations, making this disease an ongoing challenge for diffuse
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optics.
5.2 Future directions
5.2.1 Instrumentation and measurement procedures
After normal volunteer and clinical measurements, simulations, and testing, it is not
recommended to include 658 nm as a wavelength in future iterations of DOSI tech-
nology. Even though the more sensitive 3-mm APD shows improvements for 658 nm
in SNR, source-detector separation, and optical property measurements, hemoglobin
absorbs so strongly at wavelengths <700 nm it is recommended to use longer wave-
lengths for better SNR (Table 3.2) and deeper imaging.
Point measurements are time consuming and labor intensive. While the proposed
instrumentation suggests another point-scanning hand held device, recent technology
advances could make grid and point-by-point measurements obsolete. Digital Dif-
fuse Optical Spectroscopic Imaging (dDOSI) is a newer DOSI technology platform
developed by the BOTLab that uses direct digital synthesizers (DDS) and analog to
digital converters (ADC) to generate and measure frequency amplitude modulated
signals. dDOSI eliminates the need for sequential laser modulation, using wavelength
multiplexing to acquire measurements at 97 Hz (Torjesen et al., 2017). With bet-
ter detectors and faster measurement acquisition speeds, new scanning methods are
possible. For example, a mechanical gear system scanned a fiber coupled source and
detector about a single point (Applegate and Roblyer, 2018). Translations of the gear
system allowed for 3D tomographic imaging. Not only is the instrumentation speeds
improving, but the data processing speeding are too: acquiring optical properties and
chromophore concentrations in real-time in now possible using neural networks (Zhao
et al., 2018; Zhao et al., 2019). Wearable technologies are increasing in popularity,
and the BOTLab has created a continuous wave wearable device for continuous mon-
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itoring during neoadjuvant chemotherapy (Teng et al., 2017). Given that absolute
concentrations may not set prognostic thresholds, the continuous wave wearable may
be a new direction for noninvasive monitoring in the clinic.
Even without these advances in measurement acquisition and scanning, a grid
may not be necessary to detect relevant changes between normal and affected tissue.
A few measurements at the most clinically relevant points may be enough to establish
differences in tissue and monitor response.
5.2.2 Processing model
As previously discussed in Sections 2.4.1 and 3.5.1, the choice of chromophores and
light propagation model are potential limitations to this project.
The current model assumes a homogeneous sample and reported optical proper-
ties and functional information are an averaged value for the underlying tissues. A
two-layer model could improve measurements of tumor optical properties and hemo-
dynamics (Tabassum et al., 2018). Given the diversity of anatomic locations common
to sarcomas and body types, it is recommended to use a model where lipid layer thick-
ness does not need to be known (Pifferi et al., 2001).
Choice of chromophores was a potential limitation of this project. The main con-
stituents of bone is hydroxyapatite (mineral), collagen, and water (Gul-E-Noor et al.,
2015). Methemoglobin has been observed in osteosarcomas using MRI (Hosalkar and
Dormans, 2004). Inclusion of additional chromophores might improve the prognostic
capabilities of DOSI during neoadjuvant chemotherapy monitoring. However, if col-
lagen is to be included as a chromophore, careful studies showing validating diffuse
optical measurements with physiologically relevant concentrations will be necessary.
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5.2.3 Clinical studies
Until the recent advances in technology are ready for the clinic, there are still questions
to be answered with the hand held probe. This project suffers from small sample
sizes. While being one of the most comprehensive studies with 25 normal volunteers
and 9 sarcoma subjects, large subject variability necessitates larger sample sizes in
order to establish the generalizability of DOSI results for different ethnicities, ages,
and genders. Establishing the generalizability of DOSI measurements could elucidate
important chromophore similarities and differences between populations of interest
(Meertens et al., 2018).
Results from Chapter 2 show pediatric and adult populations have different chro-
mophore concentrations and preliminary results suggest sex differences in chromophore
concentrations. These results could be sample bias stemming from the small number
of volunteers measured or reflective of underlying biological differences, such as fat
storage and metabolism (Shi and Clegg, 2009; Power and Schulkin, 2008). The study
in Chapter 2 is not powered to answer these questions. However, preliminary results
show a strong correlation between lipid and hemoglobin concentration. Future anal-
yses should explore using lipids as a covariate which may explain variation within
the population and eliminate the need for different prognostic standards between
pediatric and adult populations or between men and women.
Chapter 2 is one of the first studies to quantify chromophore variation within
individuals and populations. This information will be a powerful tool for creating
future studies. For example, Chapter 3 shows that local optical contrast exists be-
tween tumor and contralateral normal regions in sarcomas, however, it is still unclear
if contrast exists between sarcomas and the normal population.
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5.3 Concluding remarks
Identification of a prognostic marker to improve sarcoma patient survival is a priority.
This project in an important step toward that objective. DOSI can measure bony
locations and sarcomas. While diffuse optical technologies have incredible potential,
development of useful NIR diagnostic thresholds have been hampered by wide vari-
ation in results (Meertens et al., 2018). This project quantifies and characterizes
functional hemodynamic information which will serve future researchers in study de-
sign and analysis. With the instrumentation improvements developed in this project
and further characterization of tissues, I remain optimistic that a prognostic marker
will be found.
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Appendix A
Optical properties from literature
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Appendix B
Phantom recipe
The following recipes were developed to create phantoms with specific µa and µ
′
s
values. The µa and µ
′
s values of all phantoms in the Biomedical Optical Technologies
Lab (BOTLab) taller than 2 cm with recorded nigrosin and TiO2 concentrations
were measured by the 1-mm APD with a 22 mm source-detector separation 3 times.
Phantoms with a negative scattering slope when fit to a power law and with a 90th
percentile SNR greater than 3 at 658 nm were included in the dataset.
As shown in Figure B·1, the average µa and µ′s were plotted against their corre-
sponding nigrosin-to-silicone and TiO2-to-silicone ratios. From linear regressions, the
following equations were identified and used to calculate the appropriate concentra-
tions of nigrosin and TiO2 for a given silicone volume (V ), µa (equation B.1),and µ
′
s
(equation B.2).
nigrosin = V (0.1382µa + 0.0001) (B.1)
TiO2 = V (0.0009µ
′
s + 0.00005) (B.2)
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Figure B·1: Recipes (line) with a 95% confidence interval for silicone
tissue-mimicking with specific (a) µa and (b) µ
′
s values at 658 nm.
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The protocol for phantom making is the following:
Materials:
• 1.5 g/L H2O nigrosin solution
• titanium dioxide (TiO2)
• curing agent
• uncured silicone
• easy release
• mixing container
• mold container
• hand-held power tool
• vacuum chamber
• sonicator
Instructions:
1. Calculate and measure quantities of 1.5 g/L H2O nigrosin solution and TiO2
2. Manually mix TiO2 and 60 mL of curing agent
3. Sonicate TiO2 mixture for 1–3 hours
4. Ten minutes prior to end of sonication, pour 600 mL of uncured silicone into
mixing container
5. Add desired amount of 1.5 g/L H2O nigrosin solution to uncured silicon and
mix for 10 min using a hand-held power tool
104
6. Add TiO2 mixture to silicone/nigrosin mixture and mix for 5 min
7. Place mixture into vacuum chamber for maximum of 30 min (surface of mixture
should be smooth with no bubbles)
8. Spray mold with easy release
9. Pour bubble-free mixture into mold
10. Place mold back in vacuum chamber, and let sit 24 hours
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